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Abstract

Some early stage NSCLC patients have a better survival prospects than others. In any
event, the long-term prognosis for NSCLC patients is poor. Various measures were
investigated to gain a better understanding of those patient characteristics that confer
better survival or predict disease recurrence. A dataset comprised of stage 1 NSCLC
patients (n=162) that underwent resection was investigated. Clinical variables (CVs) and
tissue microarray (TMA) images with DNA repair protein and standard H&E expressions
were investigated. Patients were dichotomized into two groups by survival
characteristics and logistic regression (LR) modeling was used to predict favorable
survival outcome. Various patient strata were investigated with Cox regression and
Kaplan Meier survival analysis (i.e. accepted survival analysis methods). A statistical
learning (SL) method comprised of a kernel mapping and Differential Evolution
optimization was developed to integrate SL techniques with LR and accepted survival
analysis methods by first combining various patient measures to form a hybrid variable.
Younger age, female gender, and adenocarcinoma subtype confer better survival
prospects, whereas recurrence confers poor survivability. The SL hybrid modeling
produced greater favorable outcome associations and survival hazard relationships than
the accepted approaches. Automated texture measures from the HE stained TMA
images were significantly related to survival, tumor-type, and tumor-grade. DNA repair
measures in isolation or in combination with CVs were not related to survival, favorable
outcome or recurrence, and none of the CVs were related to recurrence.
v

A platform was established to incorporate automated TMA analysis and SL techniques
into standard epidemiologic practice, and baseline predictive models were constructed.
Future work will investigate novel biomarkers and larger datasets using this established
framework to construct prognostic models for clinical applications for lung cancer
patients in general and to better understand disease recurrence.

vi

Chapter 1: Introduction

Lung cancer is the leading cause of cancer related mortality in the United States as well
as globally [1-3]. Primarily, there are two types of lung cancer: non-small cell lung
cancer (NSCLC), which accounts for about 80% of the cases [3], and small cell lung
cancer (SCLC), which accounts for about 15% of the cancers [4]. Smoking is the leading
risk factor for the development of lung cancer, and about 85% of lung cancer deaths are
attributed to smoking [5]. Non-small cell lung cancer originates from the epithelial cells
of the lung of the central bronchi to terminal alveoli. The common histological subtypes
of NSCLC are (a) adenocarcinoma (AC), which represents about 40 % of the cases, (b)
squamous cell carcinoma (SCC), which accounts for about 39% of the cases, and (c)
large cell carcinoma, accounting for about 15% of the cases [6]. Although the NSCLC
subtypes differ in cell size, shape, and chemical makeup, they are categorized as a
monolithic group because they are treated similarly and have a similar prognosis.

The prognosis for lung cancer patients is generally poor. The five-year survival rate for
NSCLC patients with stage IV disease is as low as 1% (see Table 1). Improvements in
therapeutic modalities have resulted in modest improvements in outcome for patients in
the past two decades. Related work by Behera et al and group shows the efficacy of
certain treatments for patients with NSCLC in different settings [7-9]. In parallel, we have
shown that SCLC patients that did not respond to frontline chemotherapy also
1

responded poorly with second-line treatments [10]. Staging of the cancer is significant
for determining suitable treatment, and patients with early stage cancer can benefit from
surgical resection [3]. However, a cure remains elusive for patients with advanced stage
disease and as well as for the majority of stage II and III patients [1, 6].

Lung cancer is often diagnosed at an advanced stage, largely due to the lack of effective
modalities for early detection [2, 11]. Recent evidence from the National Lung Screening
Trial shows that low-dose computed tomography (CT) scans can reduce lung cancer
mortality in comparison with single-view chest radiography when screening high-risk
patients [6]. Volumetric datasets and high resolution enable helical CT to better detect
early stage cancers than chest radiography [12, 13]. Before this promising approach is
incorporated into clinical practice, several important clinical issues must be addressed
[6, 11].

For patients with early stage lung cancer, local therapy with surgical resection is
associated with the best survival outcomes. This best case scenario is limited to those
with NSCLC, which accounts for approximately 85% of all cases of lung cancer in the
United States. Despite optimal surgical resection, recurrence of disease is noted in 3075 percent of the patients with early stage disease. The development of prognostic
models for predicting survival outcomes for patients with NSCLC after resection may
have important healthcare implications [14]. Even in patients with early stage lung
cancer, there is a critical need to improve cure rates, identify patients at higher risk for
recurrence, and identify those patients that have better chances of survival. Previous
work [2, 15] showed that early stage at diagnosis, younger age, and female gender are
2

favorable prognostic indicators for NSCLC patients. It is also important to note that the
incidence rates for the various forms of lung cancer appear to be shifting in time [16],
and that there are both racial and regional differences throughout the United States [17].
Both serial and geographical variations in lung-cancer survival patterns indicate that
survival rates require continual evaluation to ensure the knowledge-base is current.

The survival rates shown in Table 1 were obtained from the National Cancer Institute's
Surveillance, Epidemiology, and End Results (SEER) database based on people who
were diagnosed with NSCLC between 1998 and 2000 [18]. These clearly show that early
stage patients have a survival advantage, but the 5 year survival probability cannot be
considered favorable.
Table 1: Five year survival rate across stages

Stage

IA

IB

IIA

IIB

IIIA

IIIB

IV

5- year survival rate 49% 45% 30% 31% 14%

5%

1%

Understanding the patient attributes that enhance longer-term survival probability or
indicate recurrence is necessary to individualize treatment options. In this work, various
aspects of stage I NSCLC were investigated. Clinical, pathological, and image
measures, derived from tissue microarrays (TMAs), were analyzed. The dataset is
comprised of stage 1 NSCLC patients (n=162) that underwent resection at the WellStar
Kennestone Hospital, GA, from 2002-2008. These patients were selected
3

retrospectively and consecutively. This data was collected under an approved protocol
by the Western Institutional Review Board (WCR20080401; approval # 20081986). This
work is presented in four parts corresponding to chapters 2-5:

(i)

Analyses of survival and recurrence using readily available clinical and
pathological data.

(ii)

Study of DNA-repair pathway expression variables.

(iii)

Evaluation of statistical learning (SL) methods for survival analysis.

(iv)

Automated measurements and analyses of multispectral tissue microarray
(TMA) image data.

Part i was used to form baseline survival attributes for comparisons using readily
available variables. The patient population and measures are described in Part i except
for the tissue microarray (TMA) data and novel biomarker measures. This population
sample was used for all of the subsequent investigations discussed in this dissertation.
In Part ii, experimental biomarkers derived from novel protein stains were used to
assess whether DNA repair can add to the findings in Part i [14]. Part iii represents an
exploration to develop and evaluate a method for adapting statistical learning (SL)
methods for accepted epidemiologic analyses. In this approach, SL methods were used
as a pre-processing step to prepare the data for use in logistic regression and survival
analysis (Cox regression and Kaplan Meier analysis) [19]. This essentially combines the
strength of SL with these important epidemiologic analysis methods. In Part iv, a system
was developed to analyze TMA images automatically. TMA images were stained with
standard techniques and assessed with image processing methods to evaluate whether
4

there is additional information that is not captured by human observation. Although we
used low resolution data for this analysis due to technical difficulties, the methods are
scalable to higher resolution.

5

Chapter 2: Survival Analysis of Stage I Non-Small Cell Lung Cancer

Readily available clinical variables and pathologic features from stage I NSCLC patients
were analyzed [14]. Two forms of analysis were applied to evaluate the survival
characteristics of this population. Logistic regression (LR) modeling was used to study
two groups of patients dichotomized by their survival characteristics to form favorable
and unfavorable survival outcome groups. Various models were studied to predict
favorable outcome. Survival analysis (i.e. Cox regression and Kaplan-Meier analysis)
was also used to study various patient strata. The full dataset as well as subsets of data
dictated by full case ascertainment for the variables under consideration were used for
this work. The NSCLC patient data described below was used exclusively for this work
and will not be redefined in subsequent chapters. The evaluation described in this
chapter was essentially excerpted from the work by Behera et al [14].

2.1 Study Population and Measures
The dataset is comprised of patients (n=162) with stage I NSCLC that underwent
surgical resection at the WellStar Kennestone Hospital, GA, from 2002-2008. These
patients were selected retrospectively and consecutively. The selection criteria included
all stage I patients that had complete case ascertainment for the variables under
consideration. One hundred and one (n1) of these patients were alive at last contact
6

(censored), and 61 (n2) patients died (incident) during the course of the contact interval.
The clinical and pathological variables abstracted from the patient files included age (i.e.
age of the patient at the time of surgery) with integer accuracy, gender (binary), smoking
status (binary), four histological-subtypes [i.e. AC, SCC, LCC, and adenosquamous
carcinoma (ASC)], tumor-grade, adjuvant treatment, disease recurrence, and tumorlocation within the lung. Stage I was dichotomized as IA and IB subgroups (categorical
binary variable) as ascertained from the pathology reports. Past or current smokers (i.e.
smoking status) were categorized as either a smoker, past or present (yes), or as those
that never smoked (no). Tumor was graded with a 1-3 integer scale (tumor-grade)
describing the cancer cell differentiation (a measure of abnormality) derived from
pathology reports (i.e. grade 1 implies well differentiated cells resembling normal cells
and grade 3 implies poorly differentiated cells indicating abnormality). Adjuvant
treatment was defined as systemic chemotherapy given to the patients after surgical
removal of the tumor. Recurrence indicates the relapse of the disease after surgery.
Tumor-location was defined primarily with four categories: lower lobe, middle lobe, upper
lobe, and upper/lower lobe. This database (Winship Cancer Institute of Emory University
Lung Cancer Database) was constructed and managed by the author [20] over the past
three years (2009-2012) and is still under development. This database is a web-based
archival management system, designed and developed to store clinical and pathological
information of lung cancer cases [20]. Data from this system can be exported to SAS
and MS-Excel. The statistical analysis was performed with the SAS software package
(SAS Institute, NC) and PASW Statistics 18.0.0 (SPSS Inc).

Two forms of survival analysis were used below. First, the patients were dichotomized
into two groups based on their survival outcomes. Logistic regression (LR) was used to
7

investigate these two groups using the variables discussed above. Secondly, various
patient strata were investigated with Cox-regression and Kaplan Meier survival analysis
The rationale for using two forms of survival analysis is that they provide different
endpoints (discussed below in the Modeling Strategies Section).

2.2 Analysis Methods
2.2.1 Favorable Outcome Analysis
Censored (n1) and incident (n2) patients were used to form favorable and unfavorable
survival outcome groups, respectively. The LR modeling was referenced to the
favorable outcome group (i.e. to predict the probability of a given patient experiencing a
favorable survival outcome given a specific set of variables). Complete caseascertainment for all the variables for the entire patient population was not available. The
full dataset (full group) and various subgroups of this dataset were studied depending
upon the case-ascertainment for the variables under investigation. The goal was to find
those variables related to favorable survival outcome and characterize their association
strengths. Another aim was to find the collection of variables that provided the greatest
discrimination (i.e. predictive capability) between these groups. Odds ratios (ORs) were
used to assess group associations and the area under the receiver operating
characteristic curve (Az) was used to measure model predictive capability. The ORs are
cited with 95% confidence intervals (CIs). In this portion of the analysis, Az was
computed using standard SAS routine [i.e. assessing the range of (false positive,
sensitivity) ordered pairs and performing integration with the trapezoid rule]. To avoid
over fitting and user imposition, interaction terms within the LR model were not
considered in the favorable outcome modeling. Alternatively, variable interactions were
8

investigated as endpoints below. The justification for the favorable outcome modeling
and the dichotomization strategy are discussed in more detail in subsequent sections
and chapters. Briefly, this form of LR modeling has a different interpretation than the
time-to-event methods, and the dichotomization technique was necessitated by the
limited dataset.

2.2.2 Inter-Variable Association Analysis
Various combinations of variables were used to evaluate possible associations with the
AC and SCC histology subtypes, gender, and disease recurrence. In this modeling,
histology, gender, and recurrence were used as the dependent variables for LR. The LR
models with the following independent (or input) variables were investigated: age (A),
tumor-grade (Gr), and gender (G). The following relationships were investigated to
predict the two class histology subtypes (i.e. predict SCC): LR(A, Gr), LR(A, G), and
LR(A, Gr, G). A similar analysis was performed to predict male gender and disease
recurrence. The independent variables used in the LR model to predict male gender and
recurrence can be determined from the histology subtype analysis by replacing SCC
with male gender and disease recurrence, respectively.

2.2.3 Survival Analysis
Kaplan-Meier survival probability analysis was applied to evaluate survival differences
between various patient strata. Hazard ratios (HRs) estimated with Cox regression were
used to assess group survival characteristics with 95% CIs. To study age-related
survival, the patients were dichotomized using the population median age (i.e. 67 years)
9

as the cut-point. The below median age group was used as the reference. The patient
population was also dichotomized by two-group histology subtype (i.e. SCC and AC),
recurrence, adjuvant treatment, and gender; the respective references were AC, norecurrence, no-adjuvant treatment, and female gender. Additionally, stage I subgroups
were investigated in various strata (i) IA and IB using IA as the reference using the full
group dataset, (ii) lower age-group patients with stage IA histology as the reference
compared to the remaining patients in the full group dataset, (iii) all patients with stage
IA with AC as the reference compared to those remaining patients in the full group, and
(iv) lower-age group patients with both stage IA and AC as the reference compared to
remaining patients in the full group.

2.2.4 Modeling Strategies
These two forms of modeling (i.e. time-to-event and LR favorable outcome analysis)
convey different information to both the patient and the clinician. Cox regression is not
typically used to make point estimates at the patient level [21] but can provide an
instantaneous relative risk given a set of covariates for a given patient. Developing
methods derived from Cox regression for point estimates is an active field of research
[21]. Kaplan-Meier analysis is non-parametric and not useful for point estimates.
Reducing the data resolution to a binary outcome makes the dataset amenable to both
LR modeling for point estimates specifically and more generally to all forms of binary
classification applications. The LR model provides the probability of a pre-defined
endpoint given a set of specific covariates and thus gives an output that is easily
interpretable at the patient level. More generally, converting survival data to a binary
outcome (i.e. for classification purpose) is an accepted approach in survival prognosis
10

predication [22]. Our approach [14, 19] to survival analysis has a similar prognostic aim
and it also serves as a simplifying mechanism for accepted time-to-event analysis, as
demonstrated below. Thus, the dichotomized analysis and the accepted survival
analysis methods (i.e. Cox regression and Kaplan-Meier analysis) are complementary.
We also developed a non-standard dichotomization method for the binary modeling.
Often such dichotomization is based on a pre-defined survival time cut-point [22], not
incident-censored group status and is discussed in detail below.

2.3 Results
2.3.1 Patient Characteristics
Table 2 shows the patient characteristics summarized by combined population, incident
group, and censored group. The median age of the patients included in this analysis
was 67 years. There was a near equal representation of male and females in total. The
censored patients were younger, more likely to have tumor-grade 1 than those in the
incident group, whereas the other grades were similar across the groups. The censored
patients were more likely female and to have AC rather than SCC histology. Although
only a small number of patients had either ASC or LCC histology-subtypes, those in the
censored group were more likely to have LCC than those in the incident group. Smoking
status was similar across the groups, and approximately 20% of the patients were nonsmokers. The incident patients were more likely to have experienced disease recurrence
and received adjuvant treatment. Tumor-location (upper lobe, lower lobe, middle lobe,
upper/lower, upper/middle, lower/middle, chest wall, main stem bronchus) was similar
across the groups. The censored patients were more likely to have stage IA disease in
comparison with the incident patients. For the favorable group, the censored time
11

distribution mean and standard deviation (SD) were 3.94 and 1.3 years, respectively.
For the unfavorable group, the overall survival time distribution mean and SD were 2.19
and 1.8 years, respectively (not shown in the table). The separation between the group
means provides the justification for the stratification method. The incident group patients
are more likely positive for recurrence, but roughly 64% of these patients are negative
for recurrence. It also follows that the recurrence status for most of the censored group
patients is unknown. This suggests that the recurrence variable in this work could be
qualified more accurately as early recurrence.
Table 2: Patient characteristics. This table provides the patient characteristics (Char) for
the incident group (I), censored group (C), and combined total (Tot). The number of
samples (n), mean values (Mean), standard deviation (SD) and percentages (%) are
provided for each characteristic where applicable. The C and I labels correspond to the
favorable and unfavorable outcome groups, respectively.
I

C

Tot

Char
N

Mean / SD

N

Mean / SD

n

Mean / SD

Age

61

or %
69.6 / 7.66

101

or %
65.7 / 8.6

162

or %
67.2 / 8.4

Tumor-Grade

61

2.23 / 0.62

101

2.10 / 0.69

162

2.15 / 0.66

One

6

9.84%

19

18.81%

25

15.43%

Two

35

57.38%

53

52.48%

88

54.32%

Three

20

32.79%

29

28.71%

49

30.25%

Male

39

63.93%

39

38.61%

78

48.15%

Female

22

36.07%

62

61.39%

84

51.85%

Gender
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Table 2 (Continued)
Tumor-type
Adenocarcinoma

30

49.18%

63

62.38%

93

57.41%

Adenosquamous

2

3.28%

2

1.98%

4

2.47%

Large Cell

2

3.28%

11

10.89%

13

8.02%

Squamous

26

42.62%

22

21.78%

48

29.63%

Unknown

1

1.64%

3

2.97%

4

2.47%

Non-Smoker

12

19.67%

19

18.81%

31

19.14%

Smoker

47

77.05%

74

73.27%

121

74.69%

Unknown

2

3.28%

8

7.92%

10

6.17%

Yes

20

32.79%

6

5.94%

26

16.05%

No

39

63.93%

93

92.08%

132

81.48%

Unknown

2

3.28%

2

1.98%

4

2.47%

Lower Lobe

18

29.51%

26

25.74%

44

27.16%

Middle Lobe

5

8.20%

5

4.95%

10

6.17%

Upper Lobe

36

59.02%

63

62.38%

99

61.11%

Upper/Lower Lobes

0

0.00%

2

1.98%

2

1.23%

Upper/Middle Lobes

0

0.00%

1

0.99%

1

0.62%

Chest Wall

0

0.00%

1

0.99%

1

0.62%

Main Stem Bronchus

0

0.00%

1

0.99%

1

0.62%

Unknown

2

3.28%

2

1.98%

4

2.47%

Smoking

Recurrence

Tumor-Location

13

Table 2 (Continued)
Treatment
Yes

10

16.39%

9

8.91%

19

11.73%

No

51

83.61%

92

91.09%

143

88.27%

A

37

60.66%

73

72.28%

110

67.90%

B

24

39.34%

28

27.72%

52

32.10%

Stage I

2.3.2 Favorable Outcome Analysis
For the full group dataset (n=162, with n1=101 and n2 = 61), complete case
ascertainment for age, gender, adjuvant treatment, tumor-grade, stage I subgroup was
available. The forward stepwise selection procedure used with LR resulted in a bivariate
model. As shown in Table 3, the ORs for age and gender were significant (i.e. the CIs do
not include unity). When adjusting for gender, the age association [OR = 0.64 per
standard deviation (SD) increase] and gender association [OR = 0.39] show increasing
age and male gender confer an unfavorable survival outcome (i.e. females are 2.6 times
more likely to be in the favorable group and younger age patients are 1.5 times more
likely to be in the favorable group). In this age-gender model, Az = 0.683. Adjuvant
treatment, tumor-grade, and stage I subgroup measures were not significant
independent predictive factors (i.e. Az < 0.600) and their OR associations were not
significant. We estimated the standard error (SE) in Az was 0.035.
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Table 3: Favorable outcome predictions and associations. The full group modeling used
to predict favorable outcome included: age (A), gender (G), adjuvant treatment (T) noted
as ‘Treat’ in the covariates (Cov) column, tumor-grade (Gr), stage I subgroup (S1). The
step-forward selection was used to build a model to predict the censored group (C).
Only age and gender were significant. The odds ratios (ORs) with 95% confidence
intervals are provided for each covariate, and the area under the receiver operating
characteristic curve (Az) is provided for the various arrangements. Non-applicable (NA)
entries are labeled. The functional notation LR(x,y) was used to indicate the variable(s)
within the logistic regression (LR) model used to predict the censored group.
Model

Cov

Unit / Ref

Versus Cov OR

Az

8.4

NA

0.61
(0.43, 0.87)

0.630

Female

Male

0.36
(0.18, 0.69)

0.627

LR(A) =
censored group

Age

LR(G) =
censored group

Gender

LR(T) =
censored group

Treat

No

Yes

0.50
( 0.19, 1.31)

0.537

LR(Gr )=
censored group

Grade

1.0

NA

0.74
(0.45, 1.20)

0.549

LR(S1) =
censored group

Stage

IA

IB

0.59
(0.30, 1.16)

0.558

Age

8.4

NA

Female

Male

LR(A,G )=
censored group

Gender

0.64
(0.44, 0.91)
0.39
(0.20, 0.75)

0.683

In the subgroup-1 dataset (n =149, with n1 =91 and n2= 58), patients that had complete
ascertainment for age, gender, tumor-grade, tumor-location, and histology-subtype were
included to predict favorable outcome. This modeling considered all of the measured
tumor characteristics in combination with age. The univariate analysis found significant
15

associations for age [OR= 0.65 (CI: 0.45, 0.92)] per standard deviation (SD) increase
and gender [OR=0.32 (CI: 0.16, 0.64)] per unit increase, indicating increasing age and
male gender confer an unfavorable outcome. The forward selection process resulted in
a bivariate model with age and gender, which had similar ORs as the univariate models
and Az = 0.680. None of the tumor characteristics, including stage I subgroup,
demonstrated significance (findings not shown).

The subgroup-2 dataset (n= 134 with n1= 80 and n2= 54) was investigated to predict
favorable outcome by restricting the analysis to patients that had full case ascertainment
for the SCC and AC histology-subtypes in conjunction with age, gender, tumor-location,
adjuvant treatment, tumor-grade, and stage I subgroup. The univariate analysis found
significant findings for gender [OR = 0.34 (CI: 0.17, 0.70), Az = 0.630] and histology
subtype [OR= 0.44 (CI: 0.21, 0.91) and Az=0.594]. The forward stepwise procedure
found the corresponding bivariate model with gender and histology subtype. In this
model (i) the ORs were similar to that of the respective univariate models, (ii) the
combined Az increased to 0.668, and (iii) the OR for histology was not significant. The
findings show that both AC and female gender confer a favorable survival outcome, and
these two variables in combination provided an increased Az in comparison with either in
isolation. The other variables were not significant (data not shown). It is important to
note that age was not included in the selection process. The reasons for this were
investigated below in the interaction analysis.

Different combinations of variables were investigated to determine models with
increased predictive capability for favorable outcome using the forward stepwise
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procedure. This subgroup is referred to as the best model dataset (n= 123 with n1=71
and n2=52). This evaluation included patients with complete case ascertainment for age,
gender, adjuvant treatment, tumor-grade, stage subgroup, SCC and AC histologysubtypes, tumor-location, smoking status, and recurrence. The model with the greatest
predictive capability included gender, histology, and recurrence, which resulted in a
combined Az of 0.788. In this model the associations for gender [OR = 0.32 (CI: 0.14,
0.76)], histology subtype [OR = 0.41 (CI: 0.17, 0.98)], and recurrence [OR = 0.04 (CI:
0.01, 0.20)] were significant and all conferred an unfavorable outcome. The respective
ORs do not vary much from their respective univariate values (see Table 3) indicating
they provide independent contributions. Age was then forced into the selected model.
Although the OR association for age was not significant, its contribution increased the
model’s predictive capability giving Az = 0.796. Although recurrence was a strong
indicator of limited survival, the variable has limited application in general predictive
modeling in that over 63% of patients in the unfavorable group were negative for
recurrence as was over 94% of those patients in the censored group (i.e. not known).
However, understanding the variables related to recurrence is important because given
recurrence, poor survival is likely.

2.3.3 Interaction Analysis
To understand possible interactions between age and other variables, intermeasurement analyses were performed using the subgroup 2 patients. This analysis
was portioned into three outcomes by considering those variables that could predict (i)
the two-subgroup histology [i.e. AC or SCC], (ii) gender, and (iii) recurrence. To limit the
presentation, only models that provided an Az equal to or above 0.600 are shown when
17

the corresponding ORs were not significant. The Az quantities were calculated with SAS
as described in Section 2.2. The histology relationships are shown in Table 4. Although
there are many models that provided some predictive capability, the majority of the OR
associations were not significant. In all models that contained age, increasing age was
associated with SCC. The association for age in isolation was [OR = 1.70 (CI: 1.14,
2.52) per SD increase] with Az = 0.637. The gender associations are shown in Table 5.
Although tumor-grade in isolation provided weak predictive capability (Az = 0.596), its
association [OR = 1.84 per unit increase] indicates increasing grade is significantly
related to male gender; in models that included grade, similar associations were found
(i.e. 1.46 - 2.01 range of ORs). To understand possible interactions with disease
recurrence, several LR models were investigated to predict recurrence. No significant
OR relationships or predictors of recurrence were found (data not shown).
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Table 4: Interaction analysis to predict histology. In this analysis we use the subgroup
two dataset to predict two class histology: adenocarcinoma (AC) and squamous cell
carcinoma (SCC). This model included age (A), gender (G), and tumor-grade (Gr). We
used the functional notation LR(x,y) to indicate the variable(s) within the logistic
regression model to predict SCC. Odds ratios (ORs) are provided with 95% confidence
intervals parenthetically. The area under the receiver operating characteristic curve (Az)
is provided for each model. The unit and reference (ref) and covariate (Cov) ORs are
also provided for each model. Non-applicable (NA) entries are labeled.
Model

Cov

Unit/Ref

Versus

LR(A)=SCC

Age

8.0

NA

Cov OR

Az

1.70
0.637
(1.14, 2.52)
1.76
Age

8.0

NA

(1.18, 2.65)
0.651

LR(A, Gr)=SCC
Grade

1

NA

1.43
(0.79, 2.58)
1.65

Age

8.0

NA

(1.11, 2.46)
0.660

LR(A, G)=SCC
Gender

Female

Male

1.71
(0.82, 3.58)
1.70

LR(A, Gr, G)=SCC

Age

8.0

NA

Grade

1

NA

(1.13, 2.56)
1.32
(0.72, 2.42)
1.58

Gender

Female

Male
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(0.74, 3.39)

0.665

Table 5: Interaction analysis to predict male gender. In this analysis we use the
subgroup-2 dataset to predict gender. This model included age (A), tumor-grade (Gr),
and histology (H), including adenocarcinoma (AC) and squamous cell carcinoma (SCC).
We use the functional notation LR(x,y) to indicate the variable(s) within the logistic
regression model used to predict male gender. Odds ratios (ORs) are provided with
95% confidence intervals parenthetically. The area under the receiver operating
characteristic curve (Az) is provided for each model. The unit, reference (ref) and
covariate (Cov) ORs are also provided for each model. Non-applicable (NA) entries are
labeled.
Model

Cov

Unit/Ref

Vs

Cov OR

Az

LR(A)=SCC

Age

8.0

NA

1.70
(1.14, 2.52)

0.637

Age

8.0

NA

1.76
(1.18, 2.65)

LR(A, Gr)=SCC
Grade

1

NA

1.43
(0.79, 2.58)

Age

8.0

NA

1.65
(1.11, 2.46)

LR(A, G)=SCC
Gender

Female

Male

1.71
(0.82, 3.58)

Age

8.0

NA

1.70
(1.13, 2.56)

Grade

1

NA

1.32
(0.72, 2.42)

Gender

Female

Male

1.58
(0.74, 3.39)

LR(A, Gr,G)=
SCC
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0.651

0.660

0.665

2.3.4 Survival Analysis
The survival analysis statistical test results, HRs, and survival probabilities are provided
in Table 6. Figure 1 shows the dichotomous age grouping survival curves. The upperage group is at significantly greater hazard compared with the lower-age group
[HR=1.86, (CI: 1.11, 3.12)]. This table also provides proportional estimates for those
surviving past 3, 5, and 7 years. This shows that 64% of the lower-age group survived
past five years, whereas 47% of the upper-age group survived past this time. Controlling
for grade in the age hazard model was not significant [HR=1.93, (CI: 1.11, 3.12)]. Figure
2 shows the survival curves for patients with SCC compared to patients with AC
histology subtypes. Patients with SCC are at a significantly increased hazard [HR = 1.78,
(CI: 1.05, 3.01)]. Over 35% of the patients with AC survived past 7 years, whereas only
15% of the patients with SCC survived past this time. Controlling for grade with histology
subtype somewhat confounded the hazard relationship [HR= 1.68, (CI: 0.99, 2. 28)], but
the change was not significant. The elevated hazard for disease recurrence [HR = 4.16,
(CI: 2.37,7.31)] significantly limits survival (Figure 3) but note the limited number of
positive recurrence patients. As shown in Table 6, approximately 38% of the nonrecurrence patients survived past 7 years whereas none of the recurrence patients
survived past this time. Although the curves indicate adjuvant treatment limits survival
(shown in Figure 4), the findings [HR = 1.82, (CI: 0.92, 3.61)] were not significant (i.e.
considered as a trend). Figure 5 shows the gender stratified curves indicating males
have an elevated hazard [HR = 2.03, (CI: 1.20,3.43)] relative to females. However, the
favorable survival characteristic for females is present mainly for the short and mid-term.
Past seven years, survival appears similar for both genders (i.e. about 26% males and
26% of females survived).

21

Figure 1: Age survival. This shows the survival probability curves for the full (full group)
dataset. The lower-age group (upper blue curve) and upper-age group (lower brown
curve) were formed by using the median age as the cut-point. The lower-age group has
a survival advantage [HR = 1.86].
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Figure 2: Histology subtype survival. This shows the survival probability curves for
patients with either adenocarcinoma (upper blue curve) or squamous cell carcinoma
(lower brown curve) histology-types (subgroup-2). The patients with adenocarcinoma
clearly have a survival advantage [HR=1.7].
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Figure 3: Disease recurrence survival. This shows survival probability curves for
patients with disease recurrence (lower blue curve) and without recurrence (upper brown
curve) for the full group. Disease recurrence limits survival [HR= 4.16].
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Figure 4: Adjuvant treatment survival. This shows the survival probability curves
stratified for patients with treatment (lower blue curve) and without treatment (upper
brown curve) for the full group. The apparent poorer survival trend for those with
treatment [HR=1.82] was not significant.
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Figure 5: Gender survival. This shows the survival curves for males (lower brown curve)
and females (upper blue curve) for the full group. Males have a significantly elevated
hazard [HR = 2.03] compared to the females. The survival advantage for females
appears limited to the short-mid terms.
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Table 6: Survival analysis associations. This table provides the hazard ratios (HRs) with
95% confidence intervals, the Wilcoxon (Wilcox), chi-square (chi-sq), and Log-rank
(LgR) test p-values (p-val) and the percentage of patients surviving (Sur) past 3, 5, and 7
years for the various groups. The number of patients in each stratification belonging to
the censored group (nc), incident group (nI), and totals (n) for each experiment are also
provided. We show the survival statistics for age, histology subtype restricted to
adenocarcinoma (AC) and squamous cell carcinoma (SCC), disease recurrence (Rec),
adjuvant treatment (treatment), and gender. The reference (ref) groups are designated
below. Recurrence and adjuvant treatment are denoted by Rec and treatment
respectively.
Model /
Group
Survival
Age
Lower-age
group (ref)
Upper-age
group
Survival
Histology
AC
(ref)

N
n I , nC
162
61,101
82
24, 58
80
37, 43
141
56, 85
93
30, 63

SCC

48
26, 22

Survival
Rec

158
59, 99

No Rec
(ref)

132
39, 93
26
20, 6
162
61,101

Rec
Survival
Treatment
No
Treatment
(ref)

Wilcox
Ch-sq
( 5.01l)

LgR
Ch-sq
( 5.75l)

(0.025)

(0.016)

5.08
(0.024)

18.28
(0.000)

1.62
(0.203)

4.68
(0.030)

28.79
(0.000)

3.04
(0.081)

143
51, 92
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HR
(95% CI)

3 Year
% Sur

5 Year
% Sur

7 Year
% Sur

79.1%

64.4%

32.2%

63.3%

46.7%

29.1%

77.3%

57.6%

35.4%

57.3%

45.5%

15.2%

79.6%

65.0%

33.9%

33.7%

11.2%

0.00%

72.4%

59.8%

29.6%

1.86
(1.1,3.1)

1.78
(1.1,3.0)

4.16
(2.4,7.3)

1.82
(0.92,3.6)

Table 6 (Continued)
Treatment
Survival
Gender
Female
(ref)
Male

19
10, 8
162
61,101
84
22, 62
78
39, 39

9.39
(0.002)

7.27
(0.007)

63.2%

28.1%

28.1%

81.7%

67.6%

25.80
%

60.2%

44.7%

26.9%

2.03
(1.20,3.4)

Additional analysis was applied to evaluate various strata based on the stage I
subgroups (graphs and tables not shown). Stratification by stage IA and IB subgroups
did not result in a significantly different hazard. However, stratification by considering all
patients in the lower-age group with stage IA compared to the remaining population was
associated with a significant hazard [HR = 2.44, (CI: 1.30, 4.59)], indicating that older
age in combination with stage IB confers poor survival relative to the remaining stage I
population. Similarly, stratification by considering patients with both AC and Stage IA
compared to the remaining population resulted in a significant hazard [HR = 2.18, (CI:
1.22, 3.88)]. Stratification by considering patients with AC, stage IA and in the lower-age
group compared with the remaining population was associated with a significant hazard
[HR= 2.65, (CI: 1.20, 5.84)]. Thus, stage subgroup was related to survival when
considering those patients with specific clinical factors.

As previously demonstrated [19], the work also shows that the LR analysis based on the
incident and censored group for favorable outcome predictions provided a means for
determining those variables related to survival as evaluated with accepted analysis
methods (i.e. Cox regression and Kaplan Meier analysis).
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The analysis methods presented in this chapter were repeated using measures of DNA
repair protein expression in the tumor tissues of the patients from this dataset presented
in the next chapter.
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Chapter 3: Analysis of DNA Repair Pathway Expression in Stage I NSCLC

Both clinical and molecular characteristics of tumors can be used to determine
prognosis. In particular, the expression of excision repair cross complementing gene 1
(ERCC1) was shown as a prognostic factor in patients with early stage NSCLC [23].
ERCC1 plays an important role in the nucleotide excision repair pathway. Given that
DNA repair is mediated by a number of other important pathways as well, the impact of
PARP and Ku86 expression was investigated along with clinical factors [2, 15] to identify
the variables that either limit survival or confer survivability [24, 25]. Ku86 and PARP are
involved in the non-homologous end joining and base excision repair pathways
respectively. It was hypothesized that the expression of each of these proteins could
influence prognosis and treatment selection for patients with NSCLC. We also
hypothesized that these expression measures may be related to disease recurrence.

3.1 Experimental Protein Expression Biomarker Measures
DNA repair protein expression for Ku86 and PARP were evaluated as disease
biomarkers from digitally scanned, immunohistochemically stained NSCLC tissue
microarrays (TMA). A board certified pathologist reviewed selected hematoxlyin and
eosin (H&E) stained slides to confirm the diagnosis and grade of the tumors.
Subsequently, areas of interest were identified on the H&E stained slides and tissue
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cores were obtained from the corresponding areas of the originating formalin fixed
paraffin embedded tissue block using a semi-automated tissue microarrayer (Pathology
Devices, Westminster, MD). Due to the inherent histological heterogeneity of non small
cell lung carcinomas, especially adenocarcinomas, triplicate tumor tissue cores were
obtained to account for tumor heterogeneity. Immunohistochemical staining of the 4 µm
thick sections from the TMA blocks was performed using monoclonal antibodies to
Ku86(SC- 56136 Santa Cruz) and PARP (Cat # 630210; Clontech) according to the
manufacturer’s instructions for immunhistochemical staining using an automated stainer
(Dako, Carpinteria, CA). The immunohistochemically stained TMA slides were digitized
using a Nanozoomer© whole slide scanner (Olympus, Center Valley, PA). Protein
expression was evaluated from digitized, stained TMA pathology images using a
modified scoring methodology. The stain intensity was assessed for each tissue core
manually by the pathologist. A final intensity score for each patient was determined by
averaging the scores of the 3 tumor cores of a sample. This method of scoring was
repeated for every patient. The three measures were derived for each DNA repair
protein expression that measured intensity (I), proportion (P) and total score (S) [i.e.
intensity × proportion]. For Ku86, we refer to these as KI, KP, and KS, respectively.
Similarly, the corresponding PARP measures were referred to as PI, PP, and PS
respectively.

Due to the proprietary nature of the novel methodology described above, these TMA
images were not available or accessible for automated analysis. Only the manual
scoring data derived from the pathologist was available for the work presented in this
chapter.
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3.2 Study Population and Methods of Analysis
This data corresponds to the NSCCLC patients and data described in the previous
chapter. Please refer to Chapter 2, section 2.1 for the description of study population
and section 2.2 for analysis methods. Favorable outcomes were modeled in a similar
fashion. Variable interactions were also investigated. In this modeling, histology (either
AC or SCC), gender, and recurrence were used as the dependent variables for the LR
model (as demonstrated in Chapter 2). The LR models included the following variables:
age (A), tumor-grade (Gr), gender (G) and the protein expression measures. Each of
these clinical and pathological variables are generically referred to as CL1, and each of
the six DNA repair protein expression variables are generically referred to as PR in this
description. The following relationships were investigated to predict the two class
histology subtypes (i.e. predict SCC): LR(CL1, PR), LR(A, Gr, PR), LR(A, G, PR), and
LR (A, Gr, G, PR). This evaluation included 56 different LR models. We performed a
similar analysis to predict male gender. The independent variables used in the LR model
to predict male gender can be determined from the histology (H) subtype analysis by
replacing G with H (i.e. 56 different LR models). Various relationships were used to
predict recurrence. We refer to A, Gr, H, and G individually as the CL2 variables in this
description. We investigated, LR(CL2), LR(PR), LR(CL2, PR), LR(A, Gr), LR(A, H),
LR(A, G), LR(CL2, PR), LR(A, Gr, H), LR(A, Gr, G), LR(A, H, G), LR(A, Gr, PR), LR(A,
H, PR), LR(A,G, PR). LR(Gr, H, PR), LR(Gr, G, PR), LR(H, G, PR), LR(A, Gr, H, PR),
LR(A, H, G, PR), LR(Gr, H, G, PR), LR(A, Gr, H, G, PR). This evaluation included 110
LR models. The models were formed manually (without automated selection). For the
survival analysis using DNA repair expression measures, similar methods were followed,
as described in Chapter 2, section 2.2.
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3.3 Results
3.3.1 Favorable Outcome Analysis
The additional patient characteristics for biomarker groups are summarized in Table 7 by
incident and censored group. The Ku86 and PARP expression for each of the three
measures were similar across the two groups. In the modeling and survival analyses
below, KI findings were excluded because all males had KI =3, as did most females
(majority of patients had the same value).
Table 7: Patient characteristics for biomarker groups. This table provides the patient
characteristics for the incident group (I), censored group (C), and total (Tot) for the
biomarkers. The number of samples (n), mean values (Mean), standard deviation (SD)
and percentages (%) are provided for each characteristic where applicable. The C and I
labels correspond to the favorable and unfavorable outcome groups, respectively.
I

C

Tot

Biomarker
n

Mean / SD

Mean / SD

n

n

or %

or %

Mean / SD
or %

KP

61

96.9 / 6.6

101

97.1 / 4.0

162

97.1 / 5.1

KS

61

289.5 /24.8

101

288./ 21.5

162

288.7 / 22.7

PI

61

2.58 / 0.60

101

2.51 / 0.62

162

2.54 / 0.61

PP

61

83.6 / 17.5

101

84.9 / 18.2

162

84.4 /17.9

PS

61

223.4/ 76.9

101

221.6 /77.4

162

222.8 / 76.7
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For the full group dataset (n=162, with n1=101 and n2 = 61), the DNA repair protein
expression measures were not significant independent predictive factors for favorable
outcome (i.e. Az < 0.600) and their OR associations were not significant as shown in
Table 8.

Table 8: DNA repair associations for the full group dataset. The odds ratios (ORs) with
95% confidence intervals, and area under the receiver operating characteristic curve
(Az) are provided for the various arrangements. We use the functional notation LR(x,y)
to indicate the variable(s) within the logistic regression (LR) model used to predict the
censored group. The unit and reference (ref) and covariate (Cov) ORs are also provided
for each model.

Model

Cov

LR(KP)=censored
group

KP

LR(KS)=censored
group

KS

LR(PI)=censored
group

PI

LR(PP)=censored
group

PP

LR(PS)=censored
group

PS

Unit/Ref
5.121
22.753
0.612
17.896
76.711

Cov OR
1.03
(0.75, 1.41)
0.95
(0.68, 1.32)
0.90
(0.65, 1.25)
1.08
(0.79, 1.47)
0.98

Az
0.479
0.530
0.527
0.540
0.498

(0.71, 1.34)

In the subgroup-1 dataset (n =149, with n1 =91 and n2= 58), patients that had complete
ascertainment for age, gender, tumor-grade, tumor-location, histology-subtype, and DNA
repair protein expression measures were included. None of DNA repair protein
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expression measures demonstrated significant association with favorable outcome (data
not shown).

The subgroup-2 dataset (n= 134 with n1= 80 and n2= 54) was investigated by restricting
the analysis to patients that had full case ascertainment for the SCC and AC histologysubtypes in conjunction with age, gender, tumor-location, adjuvant treatment, tumorgrade, stage I subgroup, and DNA repair protein expression measures. None of the DNA
expression measures demonstrated significant association with favorable outcome or
significantly altered the associations found previously in Chapter 2 when modeled
simultaneously with the respective covariates (associations not shown).

3.3.2 Interaction Analysis
To understand possible interactions between age and the DNA repair protein expression
measures, inter-measurement analyses were performed using the subgroup-2 patients.
This analysis was portioned into three outcomes by considering those variables that
could predict (i) the two-subgroup histology [i.e. AC or SCC], (ii) gender, and (iii)
recurrence. To limit the presentation, only models that were associated with Az equal to
or above 0.600 are shown when the corresponding ORs were not significant.

In the LR histology association analysis, there were many models that provided some
predictive capability, whereas, the majority of the OR associations were not significant
as show in Table 9. The associations for the PARP and Ku86 expression measures
were not significant, although the gender association [OR = 2.17] gained significance in
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the LR(Gr, G, KS) model indicating males are more likely to have the SCC histology
subtype than females.

In the LR models for gender interaction analyses (Table 10), the majority of the
associations were not significant except for those provided by tumor-grade and Ku86
expression. Although grade in isolation provided weak predictive capability (Az=0.596),
its association [OR = 1.84 per unit increase] indicates increasing grade is significantly
related to male gender; in models that included grade, similar associations were found
(i.e. 1.46 - 2.01 range of ORs). Similarly, KS in isolation provided a significant
association [OR = 2.03 per SD increase] with Az = 0.635, indicating a relationship with
gender (i.e. increasing KS is related to male gender). In most models that included KS, it
provided significant associations (i.e. 1.84 - 2.14 range of ORs). Histology gained
significance when including KS. In this bivariate model the associations for histology
subtype, [OR=2.14] and KS [OR = 2.05 per SD increase] with the Az = 0.681, show
males are more likely to have SCC and an increased KS measure.

To understand possible interactions with disease recurrence, several (i.e. 110) LR
models were investigated. We found only weak predictors of recurrence with no
significant OR relationships. For example in summary, no univariate model was
associated with an Az greater than 0.582 (provided by tumor-grade), no bivariate model
had an Az greater than 0.619 (grade and PI), no trivariate model had an Az greater than
0.625 (grade, gender, PI), and no models with four variates resulted in an Az as large as
the best trivariate model (data not shown).
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Table 9: Histology association analysis. In this analysis we use the subgroup-2 dataset
to predict two class histology: adenocarcinoma (AC) and squamous cell carcinoma
(SCC). This model included age (A), gender (G), Adjuvant treatment (T) tumor-grade
(Gr), stage I subgroup (S1), and tumor-location (Loc), and DNA expression measures.
We use the functional notation LR(x,y) to indicate the variable(s) within the logistic
regression model used to predict SCC. The unit and reference (ref) and covariate (Cov)
ORs are also provided for each model with 95% confidence intervals (CIs).

Model
LR(A, PI)=SCC

LR(A, PP)=SCC

LR(A, PS)=SCC

LR(A, KP)=SCC

LR(A, KS)=SCC

LR(G, PI)=SCC

LR(G, PS)=SCC

LR(G, KP)=SCC

LR(G, KS)=SCC

Cov

Unit/RefS

Versus

Cov OR

Age

7.967

NA

1.75 (1.17, 2.62)

PI

0.605

NA

0.82 (0.57, 1.18)

Age

7.967

NA

1.70 (0.14, 2.53)

PP

18.082

NA

0.98 (0.68, 1.42)

Age

7.967

NA

1.74 (1.17, 2.60)

PS

75.787

NA

0.87 (0.60, 1.25)

Age

7.967

NA

1.70 (1.15, 2.52)

KP

3.601

NA

0.97 (0.67, 1.40)

Age

7.967

NA

1.73 (1.16, 2.58)

KS

19.677

NA

0.75 (0.51, 1.12)

Gender

Female

Male

1.99 (0.96, 4.14)

PI

0.605

NA

0.85 (0.59, 1.21)

Gender

Female

Male

1.95 (0.94, 4.03)

PS

75.787

NA

0.91 (0.63, 1.30)

Gender

Female

Male

1.93 (0.93, 4.02)

KP

3.601

NA

0.95 (0.66, 1.37)

Gender

Female

Male

2.24 (1.05, 4.77)

KS

19.677

NA

0.72 (0.50, 1.05)
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Az
0.652

0.637

0.643

0.639

0.652

0.605

0.604

0.604

0.623

Table 9 (Continued)

LR(A, Gr, PI)=SCC

LR(A, Gr, PP)=SCC

LR(A, Gr, PS)=SCC

LR(A, Gr, KP)=SCC

LR(A, Gr, KS)=SCC

LR(A, G, PI)=SCC

LR(A, G, PP)=SCC

Age

7.967

NA

1.82 (1.20, 2.76)

Grade

1

NA

1.42 (0.79, 2.58)

PI

0.605

NA

0.82 (0.57, 1.18)

Age

7.967

NA

1.77 (0.18, 2.67)

Grade

1

NA

1.44 (0.79, 2.60)

PP

18.082

NA

0.96 (0.66, 1.39)

Age

7.967

NA

1.82 (1.20, 2.75)

Grade

1

NA

1.44 (0.79, 2.61)

PS

75.787

NA

0.86 (0.60, 1.24)

Age

7.967

NA

1.77 (1.18, 2.66)

Grade

1

NA

1.44 (0.79, 2.60)

KP

3.601

NA

0.96 (0.66, 1.38)

Age

7.967

NA

1.82 (1.20, 2.75)

Grade

1

NA

1.50 (0.82, 2.74)

KS

19.677

NA

0.73 (0.49, 1.10)

Age

7.967

NA

1.70 (1.13, 2.56)

Gender

Female

Male

1.80 (0.85, 3.81)

PI

0.605

NA

0.80 (0.55, 1.15)

Age

7.967

NA

1.65 (1.11, 2.47)

Gender

Female

Male

1.71 (0.82, 3.59)

PP

18.082

NA

0.97 (0.67, 1.41)

NA

1.70 (1.13, 2.55)

Age
LR(A, G, PS)=SCC

LR(A, G, KP)=SCC

7.967

Gender

Female

Male

1.77 (0.84, 3.73)

PS

75.787

NA

0.84 (0.58, 1.22)

Age

7.967

NA

1.66 (1.11, 2.47)

Gender

Female

Male

1.75 (0.93, 3.72)

KP

3.601

NA

0.93 (0.64, 1.35)

38

0.660

0.653

0.660

0.651

0.667

0.680

0.662

0.670

0.665

Table 9 (Continued)

LR(A, G, KS)=SCC

LR(Gr, G, PI)=SCC

LR(Gr, G, KS)=SCC

LR(A, Gr, G,PI)=SCC

LR(A,Gr,G,PP)=SCC

LR(A,Gr,G, PS)=SCC

LR(A,Gr,G, KP)=SCC

LR(A,Gr,G, KS)=SCC

Age

7.967

NA

1.68 (1.12, 2.53)

Gender

Female

Male

2.04 (0.94, 4.43)

KS

19.677

NA

0.69 (0.45, 1.05)

Grade

1

NA

1.14 (0.64, 2.02)

Gender

Female

Male

1.93 (0.92, 4.07)

PI

0.605

NA

0.85 (0.59, 1.22)

Grade

1

NA

1.17 (0.65, 2.10)

Gender

Female

Male

2.17 (1.01, 4.66)

KS

19.677

NA

0.72 (0.49, 1.05)

Age

7.967

NA

1.75 (1.16, 2.66)

Grade

1

NA

1.30 (0.70, 2.40)

Gender

Female

Male

1.67 (0.77, 3.61)

PI

0.605

NA

0.80 (0.56, 1.16)

Age

7.967

NA

1.71 (1.13, 2.59)

Grade

1

NA

1.32 (0.72, 2.45)

Gender

Female

Male

1.59 (0.74, 3.39)

PP

18.082

NA

0.96 (0.66, 1.39)

Age

7.967

NA

1.75 (1.15, 2.66)

Grade

1

NA

1.32 (0.72, 2.44)

Gender

Female

Male

1.64 (0.76, 3.52)

PS

75.787

NA

0.84 (0.58, 1.22)

Age

7.967

NA

1.71 (1.13, 2.58)

Grade

1

NA

1.33 (0.72, 2.44)

Gender

Female

Male

1.63 (0.75, 3.52)

KP

3.601

NA

0.92 (0.63, 1.34)

Age

7.967

NA

1.75 (1.15, 2.66)

Grade

1

NA

1.36 (0.73, 2.53)

Gender

Female

Male

1.89 (0.85, 4.16)

KS

19.677

NA

0.68 (0.45, 1.04)

39

0.681

0.604

0.624

0.678

0.666

0.672

0.665

0.683

Table 10: Gender association analysis. In this analysis we use the subgroup-2 dataset
to predict gender. This model included age (A), Adjuvant treatment (T) tumor-grade
(Gr), histology (H) including adenocarcinoma (AC) and squamous cell carcinoma
(SCC), stage I subgroup (S1), tumor-location (Loc), and the DNA expression measures.
We use the functional notation LR(x,y) to indicate the variable(s) within the logistic
regression model used to predict male gender. The unit and reference (ref) and
covariate (Cov) ORs are also provided for each model.
Model

Cov

Unit/Ref Versus

LR(KP)=MALE

KP

3.601

NA

1.46 (0.98, 2.17) 0.625

LR(KS)=MALE

KS

19.677

NA

2.03 (1.08, 3.82) 0.635

Age

7.967

NA

1.32 (0.93, 1.88)

PI

0.605

NA

1.26 (0.89, 1.80)

Age

7.967

NA

1.35 (0.95, 1.92)

PP

18.082

NA

1.08 (0.76, 1.52)

Age

7.967

NA

1.32 (0.93, 1.88)

PS

75.787

NA

1.22 (0.86, 1.73)

Age

7.967

NA

1.33 (0.93, 1.91)

KP

3.601

NA

1.43 (0.96, 2.11)

Age

7.967

NA

1.33 (0.93, 1.92)

KS

19.677

NA

1.96 (1.05, 3.65)

Grade

1

NA

1.88 (1.07, 3.29)

PI

0.605

NA

1.34 (0.94, 1.91)

LR(A, PI)=MALE

LR(A, PP)=MALE

LR(A, PS)=MALE

LR(A, KP)=MALE

LR(A, KS)=MALE

LR(Gr, PI)=MALE

40

Cov OR

Az

0.607

0.585

0.600
0.654

0.666

0.623

Table 10 (Continued)
LR(Gr, PP)=MALE

LR(Gr, PS)=MALE

LR(Gr, KP)=MALE

LR(Gr, KS)=MALE

LR(H, PI)=MALE

LR(H, PP)=MALE

LR(H, PS)=MALE

LR(H, KP)=MALE

LR(H, KS)=MALE

LR(A, Gr, PI)=MALE

Grade

1

NA

1.82 (1.05, 3.17)

PP

18.082

NA

1.08 (0.76, 1.52)

Grade

1

NA

1.84 (1.06, 3.21)

PS

75.787

NA

1.27 (0.89, 1.81)

Grade

1

NA

1.80 (1.03, 3.14)

KP

3.601

NA

1.43 (0.97, 2.10)

Grade

1

NA

1.75 (1.00, 3.07)

KS

19.677

NA

1.94 (1.05, 3.60)

Histology AC

SCC

2.00 (0.96, 4.15)

PI

NA

1.34 (0.94, 1.92)

Histology AC

SCC

1.90 (0.92, 3.90)

PP

NA

1.10 (0.78, 1.56)

Histology AC

SCC

1.95 (0.94, 4.03)

PS

NA

1.29 (0.91, 1.83)

Histology AC

SCC

1.93 (0.93, 4.01)

KP

NA

1.47 (0.98, 2.19)

Histology AC

SCC

2.14 (1.01, 4.55)

KS

19.677

NA

2.05 (1.10, 3.80)

Age

7.967

NA

1.41 (0.97, 2.05)

Grade

1

NA

2.04 (1.14, 3.64) 0.655

PI

0.605

NA

1.28 (0.89, 1.84)

0.605

18.082

75.787

3.601

41

0.584

0.624

0.646

0.655

0.607

0.573

0.610

0.660

0.681

Table 10 (Continued)

LR(A, Gr, PP)=MALE

LR(A, Gr, PS)=MALE

LR(A, Gr, KP)=MALE

LR(A, Gr, KS)=MALE

LR(A, H, PI)=MALE

Age

7.967

NA

1.45 (1.00, 2.10)

Grade

1

NA

2.00 (1.13, 3.56) 0.652

PP

18.082

NA

1.04 (0.73, 1.48)

Age

7.967

NA

1.42 (0.98, 2.05)

Grade

1

NA

2.00 (1.13, 3.56) 0.652

PS

75.787

NA

1.21 (0.85, 1.73)

Age

7.967

NA

1.43 (0.98, 2.07)

Grade

1

NA

1.96 (1.10, 3.49) 0.685

KP

3.601

NA

1.38 (0.94, 2.02)

Age

7.967

NA

1.42 (0.98, 2.07)

Grade

1

NA

1.90 (1.07, 3.39) 0.696

KS

19.677

NA

1.84 (1.01, 3.35)

Age

7.967

NA

1.24 (0.86, 1.78)

SCC

1.80 (0.85, 3.83)

Histology AC

0.634

LR(A, H, PP)=MALE

LR(A, H, PS)=MALE

PI

0.605

NA

1.30 (0.91, 1.87)

Age

7.967

NA

1.28 (0.89, 1.83)

Histology AC

SCC

1.70 (0.81, 3.57) 0.621

PP

18.082

NA

1.08 (0.76, 1.53)

Age

7.967

NA

1.24 (0.86, 1.79)

Histology AC

SCC

1.76 (0.83, 3.72)

PS

NA

1.25 (0.87, 1.78)

0.627
75.787
42

Table 10 (Continued)
Age
LR(A, H, KP)=MALE

LR(A, H, KS)=MALE

LR(Gr, H, PI)=MALE

LR(Gr, H, PP)=MALE

LR(Gr, H, PS)=MALE

7.967

NA

1.26 (0.87, 1.82)

Histology AC

SCC

1.74 (0.82, 3.69) 0.681

KP

3.601

NA

1.44 (0.97, 2.14)

Age

7.967

NA

1.24 (0.85, 1.81)

Histology AC

SCC

1.94 (0.89, 4.20) 0.698

KS

19.677

NA

1.99 (1.07, 3.68)

Grade

1

n/a

1.85 (1.05, 3.26)

Histology AC

SCC

1.94 (0.92, 4.08) 0.643

PI

0.605

NA

1.37 (0.95, 1.97)

Grade

1

NA

1.79 (1.02, 3.13)

Histology AC

SCC

1.84 (0.88, 3.82) 0.620

PP

18.082

NA

1.08 (0.76, 1.53)

Grade

1

NA

1.81 (1.03, 3.18)

Histology AC

SCC

1.89 (0.90, 3.96) 0.641

PS

75.787

NA

1.29 (0.90, 1.85)

Grade

1

NA

1.76 (1.00, 3.10)

SCC

1.87 (0.89, 3.92)

Histology AC
LR(Gr, H, KP)=MALE

LR(Gr, H, KS)=MALE

0.676
KP

3.601

NA

1.43 (0.97, 2.12)

Grade

1

NA

1.71 (0.97, 3.01)

Histology AC

SCC

2.07 (0.96, 4.43) 0.695

KS

NA

1.95 (1.07, 3.56)

19.677
43

Table 10 (Continued)

LR(A,Gr, H,PI)=MALE

LR(A,Gr,H,PP)=MALE

LR(A,Gr,H,PS)=MALE

LR(A,Gr,H,KP)=MALE

LR(A,Gr,H,KS)=MALE

Age

7.967

NA

1.33 (0.91, 1.95)

Grade

1

NA

1.99 (1.11, 3.57)

Histology AC

SCC

1.69 (0.79, 3.65) 0.667

PI

0.605

NA

1.32 (0.91, 1.90)

Age

7.967

NA

1.38 (0.95, 2.02)

Grade

1

NA

1.95 (1.09, 3.49)

Histology AC

SCC

1.59 (0.75, 3.39)

PP

18.082

NA

1.05 (0.73, 1.49)

Age

7.9679

NA

1.34 (0.91, 1.96)

Grade

1

NA

1.95 (1.09, 3.49)

Histology AC

SCC

1.65 (0.77, 3.54)

PS

75.787

NA

1.24 (0.86, 1.78)

Age

7.967

NA

1.35 (0.92, 1.99)

Grade

1

NA

1.91 (1.06, 3.42)

Histology AC

SCC

1.63 (0.76, 3.51)

KP

3.601

NA

1.39 (0.95, 2.05)

Age

7.967

NA

1.33 (0.90, 1.97)

Grade

1

NA

1.84 (1.02, 3.30)

Histology AC

SCC

1.81 (0.82, 3.97)

KS

NA

1.86 (1.03, 3.36)

19.677

44

0.666

0.662

0.703

0.717

In summary, the favorable outcome modeling produced little when using these novel
DNA repair markers.

3.3.3 Survival Analysis
The DNA repair protein expression survival findings are shown in Table 11. None of
these measures showed significance. The PI measure showed the strongest trend [HR =
1.49]. Approximately 64% of the patients in the lower PI group survived past 5 years,
whereas 45% of the patients in the upper PI group survived past this time. These
findings (i.e. no relationship to hazard) reinforce the principle discussed earlier that the
favorable outcome findings parallel the survival analysis findings for a given variable.

Table 11: DNA repair expression measures and survival. This table provides the hazard
ratios (HRs) with 95% confidence intervals, the Wilcoxon (Wil), Chi-square (Chi-sq), and
Log-rank (LgR) test p-values and the percentage of patients surviving (Sur) past 3, 5,
and 7 years for the various DNA expression measures. Patients were dichotomized by
their respective expression distribution median values (i.e described as low and high).
The number of patients in each stratification belonging to the censored group (nc),
incident group (nI) and totals (n) for each experiment are also provided.

Model /
Group
Survival
KP
Low-KP

N
(nI, nC)
162
(61,101)
67
(26, 41)

Wil
Chi-Sq
(p-val)

LgR
Chi-Sq
(p-val)

HR
(95% CI)

0.21
(0.64)

0.02
(0.87)

0.96
(0.58,1.6)

45

3
Year
%
Sur

5
Year
%
Sur

7
Year
%
Sur

69.95
%

55.28
%

29.94
%

Table 11 (Continued)
High-KP
Low-KS
High-KS
Survival
PI
Low-PI
High-PI
Survival
PP
Low-PP
High-PP
Survival
PS
Low-PS
High-PS

95
(35, 60)
68
(26, 42)
94
(35, 59)
162
(61,101)
76
(27, 49)
89
(34, 52)
162
(61, 101)
72
(30, 42)
90
(31, 59)
162
(61,101)
77
(30, 47)
85
(31, 54)

1.01
(0.31)

0.52
(0.46)

0.26
(0.61)

2.23
(0.13)

0.15
(0.69)

0.61
(0.43)

72.25
%
70.40
%
71.95
%

56.41
%
55.64
%
56.18
%

23.81
%
29.67
%
23.71
%

74.77
%
69.69
%

64.13
%
44.65
%

33.23
%
33.49
%

67.91
%
74.00
%

53.60
%
57.74
%

31.26
%
22.50
%

72.39
%
70.26
%

59.95
%
48.96
%

31.06
%
36.72
%

1.49
(0.88, 2.5)

0.90
(0.55, 1.5)

1.23
(0.7, 2.07)

The analysis of this population of stage I NSCLC patients is continued in the following
chapter using the novel statistical learning (SL) methods.
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Chapter 4: A Fusion of Statistical Learning Techniques with Accepted
Epidemiologic Applications

4.1 Background
Statistical learning (SL) techniques with kernel mappings can provide benefits when
addressing complicated decision problems [26-28]. These techniques are capable of
capturing non-linear input-output characteristics, operating on small datasets with
feature correlation, and do not require modeling or distribution assumptions. These
attributes are not derived without tradeoffs. These methods do not provide an output that
has a useful epidemiologic interpretation and their training often requires specialized
techniques. In contrast, logistic regression (LR) modeling, Kaplan-Meier analysis, and
Cox regression provide important epidemiologic interpretations and are used extensively
due to their availability.

The goal of this work primarily was to demonstrate and evaluate a method of fusing SL
with accepted epidemiologic practice using this dataset of lung cancer patients as an
example and test-bed. The work in this chapter was excerpted from Behera et al [19]. To
meet this objective, it was necessary to develop a platform to implement kernel based
SL methods efficiently, which will also support future studies. A technique validated
here, (applied in Chapter 2) was used as an efficiency gain. This shows that either non47

parametric Az analysis (i.e. without modeling) or LR in conjunction with Az analysis can
be used as a sifting or filtering mechanism to find variables that influence the probability
of survival characterized by either HRs or Kaplan-Meier comparisons. Although the LR
model fusion with SL provides an important interpretation and application in its own right,
it is relatively simple to estimate Az within our programming language, whereas
incorporating Cox regression or Kaplan Meier analysis as intermediary steps within our
processing routines would require considerable code development. Thus, the use of
binary separation analysis (used in the favorable outcome modeling) in conjunction with
SL based survival analysis also represents an import efficiency step in the hybrid
analysis.

To adapt SL methodology for epidemiologic application, a probabilistic neural network
(PNN) [29] was combined with LR modeling and survival analyses (i.e. Kaplan-Meier
analysis and Cox regression) to demonstrate the concept. This hybrid approach
combines the strengths of the SL methodology with these important epidemiologic
techniques. The PNN is a statistically inspired neural network [29] that uses a kernel
mapping [30, 31] to estimate the underlying probabilities. The PNN was adapted to
provide a patient score, which is different use than its intended classification application.
For the LR modeling comparisons, the favorable and unfavorable group analysis
presented in Chapter 2 was used to dichotomize the patient population for the LR
analysis. Raw clinical variables were used to form a new patient score variable with the
modified PNN. Additionally, the PNN output (i.e. the patient score) was used as the input
variable for survival analysis. There are weight parameters within the PNN (i.e. the
kernel sigma-weights) that must be estimated properly. Differential Evolution (DE) was
used for this optimization problem [32]. DE is an evolutionary computing strategy for
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global optimization tasks. Because the dataset was limited, stochastic methods were
developed to provide feedback to the DE optimization and to derive the patient PNN
scores. This new system was also evaluated with the simulated datasets and methods
described previously [33].

4.2 Methods: Modeling Techniques
4.2.1 Favorable Outcome and Survival Analysis
The non-interaction LR model [34] was used to predict favorable and unfavorable
survival outcome (explained in detail in Chapter 2). Although the work in this chapter is
presented after the work in chapters 2-3, it was performed at an earlier date [19]. The
dataset was constructed by considering those patients that has complete ascertainment
for smoking status, age, grade, and gender. For the LR analysis, we formed incident
(n=59) and censored (n=92) groups as in Chapter 2. This dataset was similar with the
various subgroups described in Chapter 2. Three variables were used in the analysis.
Age and grade were combined with the PNN to form a hybrid variable labeled as the
patient-score. Gender was incorporated as a controlling variable. The patient-score was
used as the input to LR and survival analysis (Cox regression and Kaplan Meier
Analysis). The reasons for combing age and grade are as follows. Grade showed weak
association in the previous analysis (i.e. trend only). This could imply either the
association is truly weak or it exists and could not be captured by a linear technique.
Moreover, age is continuous, and grade can be considered as a three-state continuous
variable both amenable for probability modeling, whereas the other categorical variables
do not (strictly) lend themselves to probability modeling. The hybrid variable modeling
was compared with the accepted approaches (LR and survival analysis) using age,
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grade, and gender as the inputs. In this survival analysis, patient strata were formed by
choosing the median age and median PNN score as the separation points. The other
relevant variables were introduced with both age and PNN score to evaluate their
influence on the respective survival probability curves.

As previously, for the LR modeling comparisons, ORs were used to assess
measurement association with 95% CIs and Az was used to assess predictive
capability.

For age and PNN score (i.e. the continuous variables), the LR model

coefficients were re-scaled to provide ORs per SD change for each variable. The ORs
for grade were cited in per unit increase. The Az was estimated with three methods.
First, to assess the SL training and patient scores, the definition of Az was applied [35]
using the respective distributions. Secondly, the Az quantities for the LR models were
generated within SAS as described in Chapter 2 using the output of the LR model (same
interpretation as provided by the first method). For the Kaplan-Meier analysis, chisquare Wilcoxon (more sensitive to shorter term survival differences) and log-rank (more
sensitive to longer term survival differences) tests were used for differences in
stratification. Hazard ratios with 95% CIs were estimated with Cox Regression. Thirdly,
Az was also derived from Cox regression and is a measure of the agreement between
the model and actual time-to-event outcome [36], which is a different interpretation.

4.2.2 Probabilistic Neural Network and Kernel Methods
A variation of the PNN was implemented using a Gaussian kernel, although there are
many kernels meeting the established criteria [37]. Paralleling our earlier work [38], the
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distance metric for a d dimensional input vector (i.e. the relevant patient variables) is
given by

d

( w j  w ij ) 2

j1

 2j

Di (w )  

,

Eq. (1)

where i is the patient index, wij is the jth component of the ith sample’s input vector, and
wj is the jth component of a prospective test sample’s input vector w. The sigma-weights,
σj , were estimated with DE optimization. Specifically, d = 2, with wi1 = age, and wi2 =
grade for the ith patient. The probability density estimation [30, 31] for w with n training
samples is expressed as

g (w ) 

1 n
1 n
exp[

D
(
w
)]


 k (w, w i ) .
i
n i1
n i1

Eq. (2)

Normalization factors (ignored) are discussed below. The PNN was constructed with the
above formulism for each group. For group-1, the density for w is given by

g1 ( w ) 

1 n1
 k (w, w i )
n1 i1
.

Eq. (3)

For a given w, the sum on wi is taken over group-1 samples only with n = n1. The g2(w)
density was estimated the same way by restricting the sum on wi to the group-2 samples
with n = n2. In both the g1 and g2 estimations, w included samples from both groups.
Equation (3) [i.e. the kernel mapping] also represents a function mapping of the vectors
w and wi , where each element (for fixed i) of the summation represents the inner
product of the mapped vectors [28], rendering a nonlinear problem tractable with the
proper choice of kernel. Assuming prior probabilities and misclassification costs are
equal, the PNN classifier [29] is expressed as
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g1 (w )
c
g 2 (w )
,

Eq. (4)

where c is a constant. For classification when this condition is met, w belongs to group1. Because we were interested in developing a score for each patient (not classification),
we formed a score with the above expression given by

patient-score =

g1 ( w )
.
g 2 (w )

Eq. (5)

The multivariate normalization factors were not important for this application because
both g1 and g2 contained the same sigma-weights. These scores were used with LR
modeling and the survival analysis. Because the above expression is always positive
and can be large, we used z = ln (patient-score) in the analyses as the PNN derived
patient score and performed a range compression technique to reduce statistical outlier
interference in the LR modeling.

4.2.3 Probabilistic Neural Network Training and Operation
A stochastic cross-validation technique was developed in combination with DE to
estimate the sigma-weights for the kernel in the PNN. DE is a stochastic global
optimization strategy that is self-organizing via feedback and represents an evolutionary
process. An algorithm described by the founders of DE [32] was developed and their
notation is used in this work. Important points underlying DE were discussed in our
previous work [38] and are briefly discussed here. A uniform crossover Cr = 0.9 and
scale factor F = 0.2 were used as starting points. The zero-generation vector population
(i.e. NP = 40 vectors) was initialized with uniformly distributed random variables with
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components constrained to this range [0.01, 1.5]. The vector’s components are the two
sigma-weights. For a given generation, the DE process constructs a mutant vector (or
vg) by stochastic perturbation from the current population of x, where g is the generation
index. From this, a candidate vector (or ug ) is constructed that competes with a given
current generation vector, xg , selected at random in such a way that it was not involved
with the vg (or ug ) construction. Possible solutions (xg and ug) compete against each
other using feedback from the optimization problem. The winner moves to the next
generation of x (i.e. the g+1 generation). For a given generation, there are NP
competitions. In this DE application, Az was the feedback measure using the two
patient-score distributions (i.e. for the censored and incident groups) derived from Eq.
(5). The feedback to the DE was formed by ensemble averaging derived with bootstrap
sampling [39]. For one DE generation, Nt bootstrap populations were generated. To form
a given bootstrap population, n2 samples were selected randomly from group-1 and from
group-2 with replacement. We keyed on n2 as not to bias the sampling to the larger
population. One sample from each class was selected randomly and used as w in Eq.
(5) to generate the respective patient-score quantities. The remaining samples were
used to build the respective wi populations in Eq. (5). We refer to this process as a leave
two-out stochastic cross-validation technique. When Nt = 1, the process is somewhat
similar to the conventional leave two-out approach using different realizations of the
population. This process was then repeated Nt (i.e. training) times and the average Az
was used as feedback for one DE generation. The process was terminated after G
generations. The weights that provided the largest Az were carried over to the analysis
and used to generate z for each patient using stochastic methods and ensemble
averaging. For a given w, a bootstrap population was generated from the wi population
and the respective z was generated for all n1 and n2 patients. Each patient’s z was
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derived from ensemble averaging by repeating this process for Nsc times. The training
process and final score generation flow are shown in the Figure 6 schema. The software
for the PNN and DE applications was developed recently [19] using the IDL (ITT Visual
Information Solutions, Boulder CL) programming language.

Figure 6: Modified probabilistic neural network (PNN) stochastic training and z
generation. This schema shows the PNN training for the Differential Evolution (DE)
sigma-weight vector construction, competition, and feedback from the g to the g+1
populations. The sigma-weight vectors xg and ug compete for the next generation. The
receiver operating characteristic curve area (Az ) from the stochastic cross-validation is
derived with ensemble averaging to reduce the chance of passing outliers back to the
vector competition. When g = G, the evolution stops and the sigma-weights are used in
the PNN to generate z for each patient stochastically with ensemble averaging. The z
quantities are then passed to the survival and logistic regression analyses.
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4.3 Results
4.3.1 Favorable Outcomes
The patient characteristics for this specific data subset were statistically similar to those
described in Chapter 2 and are not shown. For specific comparison reference, the
associations from the LR model (i.e. accepted approach) with age, grade, and gender
were estimated for this data subset and are provided in top portion of Table 12 for easy
reference, which are similar to those provided in Chapter 2. In the univariate age model
(Az = 0.636), the age OR = 0.60 was significant. In the grade adjusted model (Az =
0.657), the OR for age was similar and the grade OR = 0.68 was not significant. In the
grade and gender adjusted model (Az = 0.703), the age OR = 0.63 and gender OR =
0.38 were significant, whereas the grade OR = 0.73 was not significant.

55

Table 12: Odds ratios. The odds ratios (ORs) and 95% confidence intervals are
provided parenthetically for the variables used in the logistic regression modeling. The
ORs for the continuous variables (age and z) are cited per standard deviation (SD)
increase in the respective variable or as a unit increase (grade) while controlling for the
other variables when applicable. The z variable includes grade and age simultaneously.
The ORs for the other covariates (Cov) are listed in the column to the right. The area
under the receiver operating characteristic curve (Az) is also provided for each model.
Model

SD

Age OR

Az

Cov

Unit

Grade

1

Cov OR

Accepted
0.60
Age

8.681

Grade
adjusted

8.681

Grade and
Gender
adjusted

8.681

Model

(0.42,0.86)
0.58

0.636

0.657

(0.40, .83)

(0.40, 1.15)

0.63

SD

(0.43, 0.91)

ln(z) OR

0.68

0.73
0.703

Az

Grade

1

Gender

Male
vs
Female

(0.19, 0.78)

Unit

Cov OR

Cov

(0.42, 1.25)
0.38

Hybrid
z (Age and
Grade)
Gender
adjusted

1.695

4.15

0.763

(2.15, 8.01)
3.67
1.695

(1.88, 7.16)

Male
0.778 Gender
vs.
Female
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0.50
(0.24, 1.05)

The DE training for the modified PNN resulted in two sigma-weights with σ1 =
0.013610961 and σ2 = 0.35805283 for age and grade, respectively. Using Nt = 1
produced training Az values between 0.700-0.830. Choosing Nt = 5 gave consistent
findings and was used in the analysis. The stochastic cross-validation performance
coinciding with these weights gave Az = 0.710 with SE=0.03 after three generations (G =
3). These parameters were used to generate z for each patient with Nsc= 20. Processing
age and grade separately through the PNN gave Az = 0.656 for age and Az = 0.538 for
grade, which are similar to the Az values when assessing these variables individually
with LR modeling (shown in Chapter 2).

The continuous hybrid LR findings are shown in the bottom of Table 12. The combined
effect shows that for a SD increase in z (SD=1.69), the respective patient is about 4.15
times more likely to experience a favorable survival outcome (or incident group member
is 0.24 more likely to experience a favorable outcome) with Az = 0.763, which was
significantly larger (p = 0.0062) than that provided by the respective age and grade LR
model. Due to the way the PNN was defined, increasing z was protective, whereas
increasing in age was not. Adjusting for gender increased the predictive capability of the
model with Az = 0.778 (SE = 0.03), although the gender OR lost significance. Gender
also reduced the association for z with OR = 3.67 per standard deviation increase, which
was a stronger association than provided by age in the corresponding model. The Az
derived from the hybrid model (z and gender) was significantly greater than that of the
corresponding LR model with age, grade, and gender (p = 0.0173).
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To evaluate the effect of the kernel mapping on age and grade, the LR model outputs for
the two models were plotted as a function of grade and age. The left side of Figure 7
shows the grade plots for the LR (accepted approach with age and grade) model. The
respective grade plots for the hybrid LR model using z (age and grade combined) are
shown on the right side of Figure 7. In these plots, black was used to denote censored
group samples and red to denote incident group samples. The grade 1 plots for both
models exhibit similar behavior for the lower ages and show that patients 65 years of
age and younger are more likely to be in censored group. The hybrid model separates
some older grade 1 patients in contrast with the accepted LR model. A comparison of
the grade 2 plots shows that the hybrid model provides separation for the younger,
middle age, and some upper age patients, whereas the respective accepted LR model
produces confusion between the groups. In the grade 3 plots, both models provide
separation for lower age patients, whereas the hybrid model shows group separation in
the middle-age range as well. Because z is a composite variable and difficult to interpret,
the associations between age, grade, z, and group status shown in Figure 7 are also
summarized in Table 13. This provides the average values for age and the z variables
separated by grade and group.
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Figure 7: Logistic regression model output plots for each tumor-grade (1-3). The plots
on the left show the logistic regression model probabilities (P) using the age and grade
variables as the model inputs for each tumor grade. The plots on the right show the
respective hybrid logistic regression model probabilities (P) using the variable z (i.e. age
and grade combined with the probabilistic neural network) as the model input. Because
there are overlapping points (patients with the same grade and age), some points are
not distinguishable. The censored group (black) is compared with the incident group
(red). The curves were fitted with a cubic spline.
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Table 13: Age and z relationships. This table gives the mean values for age and z as a
function of tumor-grade (Grade) and censored/incident group status and combined total.
The number (n) of patients in each category is also provided.

Censored

Grade
1

Grade
2

Grade
3

Total

n

17

49

26

92

Age (mean)

66.41

66.27

63.19

65.42

z (mean)

2.11

3.91

3.12

3.36

Incident

Grade
1

Grade
2

Grade
3

All

n

6

34

19

59

Age (mean)

73.83

68.88

69.47

69.58

z (mean)

0.26

1.37

-0.07

0.8

As in the previous chapters, the overall survival (OS) and censor times were used to
form two groups because of the separation between the respective distribution means.
The favorable group had a mean censor time of 3.97 years (i.e. mean known OS time,
which is a low-side limit assuming these patients did not expire the day after studycontact), whereas the incident group had a mean OS time of 2.20 years (data not
shown). The minimum censor time (2.35 years) is greater than the mean OS time for the
incident group indicating validity of the dichotomization method, which is discussed in
more detail in Chapter 6.
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4.3.2 Survival Analysis
As above, the results from the standard methods of survival analysis are presented first.
The relevant findings for comparison are in Table 14. The hazard for age was HR = 1.72
indicating that upper-age group membership is significantly more hazardous than lowerage group membership. The longer-term survival is significantly different between the
two age groups (p < 0.050). Including grade induced a greater hazard with HR = 1.78,
but the change in the survival curves (not shown) when controlling for grade was not
significant in either the short term (p = 0.074) or the longer-term (p = 0.091). The
addition of gender caused a significant change in the survival curves compared with age
alone for both the short term (p < 0.002) and long-term survival (p < 0.005) but the HR =
1.64 lost significance (curves not shown). The grade and gender adjusted hazard for age
was HR = 1.68 (also lost significance). The statistical test findings for age and gender
are provided in Table 14 (top rows). The survival probability curves for z are shown in
Figure 8 and the HRs are provided in Table 14. The findings from these accepted
approaches follow those from Chapter 2 and are presented here for reference.
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Table 14: Hazard relationships for dichotomous age and z. For the age and z variables,
two groups were formed using the respective distribution median as the cut-point and
compared. The hazard ratios (HRs) are provided with 95% confidence intervals
parenthetically. The area under the receiver operating characteristic curves (Azs)
derived from Cox regression models are also provided. Because age and z translate
inversely with respect to hazard, increased age confers a greater hazard while
decreased z confers a greater hazard. To make HR comparisons of z with age, the
reciprocal of the z HR is required.
Model

Age HR

Az

Dichotomous Age

1.72 (1.02, 2.90)

0.5792

Grade adjusted

1.78 (1.06, 3.02)

0.606

Gender adjusted

1.64 (0.96, 2.78)

0.669

Grade Gender
adjusted

1.68 (0.99, 2.85)

0.677

Model

z HR

Az

Dichotomous z

0.25 (0.14, 0.47)

0.691

Gender adjusted

0.28 (0.15, 0.53)

0.738

Accepted

Hybrid

62

Figure 8: Survival probability curves for z. The upper and lower-z groups were formed
by dichotomizing the total collection of patients at their median z value. The upper-z
group (upper brown curve) exhibits better survival characteristics than the lower-z group
(bottom blue curve). These findings incorporate tumor-grade with age via the
probabilistic neural network combination.

The hybrid survival analysis is to be compared with the accepted approach. There is a
significant survival difference between these upper and lower-z groups (i.e combination
of age and grade) both in the short term (p < 0.0001) and long term (p < 0.0001) with HR
= 0.25 indicating those in the upper-z group are at a significantly reduced hazard
compared with those in the lower z group (i.e. the hazard for those in the lower-z
membership was HR = 4.0). About 52% of the upper-z group survived past 7 years,
whereas as about 11% of the lower-z group survived past this time. In comparison, 37%
of the lower-age (when controlling for grade) group survived past 7 years, whereas
about 29% of the upper-age group survived past this time. The addition of gender also
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produced a significant change in both short term (p = 0.0146) and the longer term (p =
0.0319) with HR = 0.28 (HR = 3.57 for lower-z membership). The associated statistical
comparisons for z and gender are provided in Table 15 (bottom two rows). As shown in
Table 14, the hybrid Cox model (i.e. using z) showed greater concordance (Az = 0.691)
with the outcome than that of the Cox model (accepted approach) using age and grade
(Az = 0.606 ), but the difference in Az was a trend (p = 0.056). Likewise, the Az
comparison between the hybrid Cox model using z and gender (Az = 0.738) with the Cox
model using age, grade, and gender (Az = 0.677) showed a similar trend (p = 0.0747).

Table 15: Survival probability statistical test summaries. The statistical tests findings
(Chi-square and p-values) for the various age and z related survival probability curves
are provided with the degrees of freedom (DF). When comparing more than two survival
curves (*), the hypothesis that all the curves were the same was tested against the
alternative that at least one curve was different.
Model

Test

Chi-Sq

DF

p-val

Dichotomous Age over
Strata

Log-Rank

4.178

1

0.0409

Wilcoxon

3.407

1

0.0649

Dichotomous Age and
Gender over Strata

Log-Rank

12.738

3

0.0052*

Wilcoxon

13.511

3

0.0043*

Log-Rank

22.759

1

<0.0001

Wilcoxon

14.941

1

0.0001

Log-Rank

28.186

3

<0.0001*

Wilcoxon

22.488

3

<0.0001*

Accepted

Hybrid
Dichotomous z over Strata

Dichotomous z and
Gender over Strata
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4.3.3 Additional Validation Analysis
4.3.3.1 Simulation Evaluation
A simulation was performed to assess the training, optimization, and patient scoring
system shown in Figure 4 under ideal conditions. The same simulation described
previously [33] was used as the input to the modified PNN. This is a two-class simulation
with two correlated input measurements and a non-linear separation boundary. Two
hundred samples per class were generated giving 400 samples total as previously [33]
for the training dataset. The training dataset was used to estimate the sigma-weights
using the algorithm described above (Figure 6). We used the same stochastic averaging
(N t= 5, and Nsc = 20) and bootstrap methods. We stopped the differential evolution
optimization for G=3 as above, which gave two sigma-weights (0.291156797,
0.0872920) with a training Az = 0.987. The training dataset was then used for wi in the
score generation using independent data. We then simulated an evaluation dataset of
the same dimension (200 per class giving 400 samples total) that was not used in the
sigma-weight generation. These new samples were then used as w in the stochastic
score generation and evaluated. This evaluation gave Az = 0.979. This shows in
principle, the system is viable and that the training distribution must be representative of
the population. It is also worth noting that the separation provided by this modified PNN
system was larger than that described previously using a different statistical learning
system when processing the same type of simulated datasets (i.e. Az ≈ 0.950).
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4.3.3.2 Traditional Holdout Cross-Validation
To assess the internal validity of the PNN score approach, we used the schema shown
in Figure 6 with one main difference. Two patient samples (one sample from each group)
were selected at random and held out (i.e. leave two-out cross-validation) of the training
process. To slow the DE convergence, we set Cr = 0.1. The system comprised of the
remaining n-2 patients was trained for 20 DE generations for each holdout pair. These
n-2 samples were used for training and for generating training z scores (age combined
with grade with the PNN) and Azs. For each DE generation, a bootstrap population was
generated from the fixed n-2 population and an Az was generated. The weights that
gave the largest Az for the 20 DE generations were used to generate the z scores for the
two samples (holdout pair). We used stochastic averaging for the output scores, where
20 bootstrap populations were generated from the fixed n-2 training samples (generated
20 scores for each of the two left out samples). This process cycled (i.e. choosing
another pair at random leaving a new n-2 training population for the next 20 DE
generations) until all patients received a score. The resulting leave two out crossvalidations gave Az = 0.700 (i.e. similar to the Az estimated from the score generation),
indicating the approach was internally valid, when generating scores for samples not
observed by the system during the training process.

4.4 Brief Statistical Learning Summary
An SL methodology comprised of DE optimization, a kernel mapping, and stochastic
ensemble averaging was presented as an illustration to generalize widely used analysis
techniques. The technique gives the SL methodology an epidemiologic interpretation.
Although a specific example was used in this work, the framework applies to all
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situations where LR modeling and survival analysis are appropriate. The approach can
be easily modified to include as many input variables as required and new samples can
be added into the training procedure with the proper clinical feedback indicating the
system can learn continually without computer processing demands due to its relative
simplicity. The system will require further evaluation with different datasets before it can
be applied in practice.
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Chapter 5: A System for Automated Measurements and Analysis of Tissue
Microarray Image Data

There are two aims of this tissue microarray (TMA) investigation. The first aim is to
develop a method of preparing and preprocessing the raw image data to allow
automated measurements for the analysis of the multispectral TMA images. The second
aim is to investigate whether various automated measures are related to some predefined endpoints. These endpoints may be survival, histology type, or tumor-grade for
example. That is, the goal is to explore the possibility of capturing different information
automatically than what a pathologist distills from tissue sections by inspection. This
work analyzes high-throughput TMA arrays stained with routine antibodies used in
pathology. This is used as developmental work and a test-bed to address the first aim. In
meeting the first aim, a framework or protocol is established for preparing TMA images
to investigate novel protein stains as potential biomarkers in the near future. Due to
technical limitations, low resolution TMA images were investigated at this time. The
intent of this preliminary investigation is to develop methods that scale easily and are
applicable to higher resolutions.

5.1 TMA Technology
Traditionally, pathology evaluation was performed with stained whole sections on slides.
Tissue microarray technology, digital pathology, and virtual microscopes are newer
additions to the pathology toolset and are widely used for research purposes. Briefly, the
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TMA construction is initiated by the pathologist’s input. Areas of interest are identified on
the H&E stained tissue sections by a pathologist. Tissue cores are obtained from the
corresponding areas of the originating formalin fixed paraffin embedded tissue block
using a semi-automated tissue microarrayer. Multiple tumor tissue cores (i.e. core
biopsies using a needle) are often taken to account for possible tumor heterogeneity.
Tissue cores are then transferred to a recipient wax block. Each recipient block contains
tissue cores from multiple patients, arranged in an array pattern. Sections of the
recipient microarray block are cut using a microtome and analyzed using standard
histological immunohistochemical stains (see Figure 9).

Figure 9: Raw TMA image. Three tumor cores and one normal core were taken from
each patient. This array contains cores from 27 patients. Each full row corresponds to
three patients (i.e. 12 core samples with four samples per patient). The lone sample at
the top left is an arbitrary spotter marker defining the proper orientation of the image.
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In this work, the digitized scans of TMA sections were obtained using the Nanozoomer
2.0 HT whole slide scanner (Hamamatsu, USA). The NanoZoomer is capable of high
magnification up to 40x objective and can process up to 210 slides at once. The
NanoZoomer uses 3-chip TDI (Time Delay Integration) line scanning method, which
accurately reproduces sample colors. The line scanning method enables the quick
production of high resolution digital slides.

5.2 TMA Image Description and Preprocessing
The TMA arrays were scanned with 20x magnification and digitized with 0.453μm per
pixel spatial resolution. A free software (Olympus, Richmond Hill, Ontario) was used to
convert the original NDPI format (i.e Hamamatsu format) images to a format (i.e. Tagged
Image File Format or TIFF) compatible with our programming language (IDL Version 8.1,
ITT Visual Information Solutions, Colorado). The converted images are multispectral
data comprised of red, green, and blue (RGB) component lower resolution images each
with 8 bits per-pixel dynamic range with 21.1μm per pixel spatial resolution. Each image
is 1280 ×1024 pixels in dimension. Each disc (i.e tissue core) is approximately 55-60
pixels in diameter and the disc spacing (separation) is about 30 pixels. Each slide of
TMA contains multiple core sections from 27 patients, as compared to the traditional
method where a section of tissue from a patient is on a single slide and reviewed by the
pathologist. The TMA allows a pathologist to evaluate several patients with a single slide
viewing.

To address aim one, operator input was combined with automated processing to prepare
or preprocess the TMA images for automated analysis. The operator input serves as a
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quality control mechanism. In principle, the arrays have four stained sections for each
patient most of which have thee malignant tissue sections (samples) and one normal
tissue control section. However, not all samples allowed for a normal control tissue
sample, leaving four malignant sections for some patients. Moreover, not all sections
were viable for automated analysis for various reasons (e.g. missing sections or over
contrast). The sections for a given patient are adjacent row-wise (in the horizontal
direction) to each other with 12 sections (i.e. cores) per row (three patients) with 9 rows
on a given full TMA image array. Our database has seven full TMA images and one
partially filled image. The rows do not necessarily run parallel to the image borders (as
exemplified in Figure 9) in most images. Samples for some patients were missing due to
poor staining and some sections for given patient were missing. The patient labeling
that relates to the sections on the image is maintained in a spreadsheet (secondarily to
the web-based database described previously). That is, the images do not contain
patient identification information. Thus, a correspondence between the image data and
patient identification (IDs) must be established.

The first step in connecting the image with the patient was to orient (or check) the
images in the proper representation and then inspect the images. The one isolated
section on the top left in Figure 9 is a spotter core (i.e an arbitrary sample) indicating that
the image is in the proper orientation. The red image (arbitrary) was used for the
preprocessing analysis. The layout of a given image was sketched on paper and each
section was labeled in accordance with the key spreadsheet containing the patient IDs.
A given image was inspected with the aim of finding one viable tumor section per
patient, because many of the normal sections were not viable. The first choice was to
select a section that was intact (appeared as a uniform disc) without background
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interference (i.e. without over contrast due to missing tissue). The core sections were
counted across each row for a given image, and the viable sections were marked on the
sketch.

The next step was automated. The background (i.e. non core sections of the image) was
segmented from the tumor section images. Segmentation was achieved with a static
pixel value threshold = 220, determined empirically. In this step, all pixel values less than
220 were set to zero. After this step, the tumor sections were separated from
background along with some stray smaller sections scattered about. In the next step, a
label region algorithm (IDL routine) was applied to the segmented image that sets each
contiguous (i.e. blobs) non-zero region within the image to a specific but arbitrary value.
Thus, all contiguous sections (all pixels within the section) in a given image now have a
unique but arbitrary value.

The following step was semi-automated. An interactive program was developed where
the operator views the image and selects the one (pre-selected) section per-patient
(using the sketch as guide) by clicking on the section. At this time (after the respective
mouse click), the computer program reads the pixel values from the selected region and
makes a mask by replacing the original pixel values for the selected region with values
equal to the patient’s ID (respective IDs were coded into the program). This process is
repeated until reaching the last sample on the respective TMA image; all of the nonselected regions are discarded during this process. This results in a mask (shown in
Figure 10, left), where each patient’s tumor section is labeled with their ID number (all
the pixels within the section have the patient’s ID number as their value). The mask is
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then inspected by sampling regions from it and making comparisons with the original
array and the sketch. Once developing the protocol described above, this procedure
takes about thirty minutes per microarray image. The same mask works for the green
and blue images because the three images are spatially aligned.

Figure 10: The mask images of the TMA image shown in Figure 9. Each patient’s tumor
section is labeled with the patient’s identification number (all the pixels within the section
have the patient’s identification number as their value) to form the binary mask (left). To
reduce edge effects further, each section was eroded in the binary-mask to account for
the filter kernel length (right). These images are over contrasted (all non-zero pixel
values set to a constant) for illustration purposes so all samples can be observed
simultaneously.

5.3 Automated Image Analysis Methods
When analyzing a given image, the patient-mask is used as a guide to acquire the
information for a given patient automatically. This works well for calculations such as
averages, standard deviations or pixel differences. Modifications are required when
applying filter kernels to analyze textures because of edge effects. Filter kernels of
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length five were used (described below). To reduce edge effects, the raw microarray
image was first filtered with the background intact, because the background was closer
to the section intensity level than that of the zero background. To achieve the final
selection, two related masks were used. From the patient-ID-mask, a binary mask was
formed by converting all non-zero valued pixels to unity giving a binary-mask. To reduce
edge effects further, each section was eroded in the binary-mask (contains the selected
samples only) to account for the filter kernel length. The final patient labeled mask
(shown in Figure 10, right) is given by: final patient-mask = eroded binary mask × the
patient ID labeled mask. The raw TMA images (red, green and blue) are then filtered
separately. The portion of the filtered image used in the analysis is then given by:
eroded binary mask × filtered raw TMA image. It was noted that the sections in the raw
image are spaced about thirty pixels apart indicating that the five element kernels cannot
span across two sections simultaneously. For a given filtered section, the standard
deviation was used as the summary measure. If kernels of larger extent were used a
simple modification is required: one section could be segmented in isolation by
embedding (center) it in a sufficiently large zero-background image, apply the filter, and
then use the same steps above modified to operate on one section at a time.

The automated image analysis considered measures derived from the raw images such
as the average (M), standard deviation (SD), and differences in pixel values between the
multispectral images. For reference each pixel has red, green, and blue components
which are defined as the vector (x1, x2, x3) = (red pixel value, green pixel value, blue
pixel value). Laws texture filters [40] were also applied to these images to assess
whether textures are related to the various outcomes. For completeness, the Laws filter
set is comprised of five one dimensional kernels. Each kernel has five elements
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expressed as: L= (1,2,6,4,1). E=(-1.-2,0,2,1), S=(-1,0,2,0,-1), and W=(-1,2,0,-2,1),
R=(1,-4,6,-4,1) referred to as level (L) , edge (E) , spot (S), wave (W), and ripple (R),
respectively. This naming convention describes the textures captured by each kernel. A
half-band filter was also applied defined as Bh = (-1,1). These filters are generically
referred to as f below and are k × 1 (k = 5 or k= 2) element column vectors. The twodimension filter kernels are obtained by the outer product of any two filters given they
have the same number of elements in this application. The two dimensional kernels are
defined as,

H  fif jT

,

Eq. (6)

where T indicates transpose and the indices define arbitrary filters (i.e. i = E and j= E,
or i = E and j = W]. For this work, we investigated two dimensional filters for i = j only.
These filters were applied to the red, green, and blue components for given section
independently. For a given binary output (i.e. AC or SQ for example), the T-test is used
to compare the measures across the two groups. After applying the filter operation, a
given component section was summarized as the standard deviation of the filtered pixel
values.

Because the multispectral data is correlated, Principal Component Analysis (PCA) [41]
was also applied to each section to reduce the three component images to one image.
For a given section, PCA was applied at pixel level and at the summary level, where the
summary measures across all samples were included. At the section or pixel level, (x1,
x2, x3) were used from a given section as the input. Assume there are m pixels in a given
section then the matrix X is an m × 3 matrix with the rows defined as xi= (x1, x2, x3)i for i =
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1 through m rows (i.e. number of pixels within the specific section). The respective
column mean is first removed from each column, and the column centered matrix is
redefined as X. The covariance matrix of X is given by

C

1
XX T
m

Eq. (7)

The Eigenvalues and Eigenvectors of C were calculated. The vector with the largest
Eigenvalue = Ep (i.e. the principal component) was used to form a new section from the
three component images by the inner product: new section = < xi , Ep> for all i. At the
summary level, the same analysis applies with the proper relabeling. Now we let m =
the number of patient samples and define the vector σi =( σ1, σ2, σ3,)i where i is the
patient index. The components [i.e. σ1, σ2, and σ3] represent the standard deviation
calculated from a given filter output or from a mixture of filter outputs for a given section.
The matrix X is formed with the rows defined as σi and the same analysis is performed.

5.4 Results
5.4.1 Tumor Histology Subtype Analysis
Because the previous work showed a survival advantage for those with AC (n=72)
compared with SCC (n=39), the measures between patients with these two histological
subtypes were compared. This data subset was developed by considering patients with
AC and SCC histology that had full ascertainment for the TMA data. Image examples
for AC and SCC are shown in Figure 11. The results from raw image analysis are
summarized in Table 16.

76

Figure 11: Raw images of SCC and AC. This shows single tumor cores from SCC (left)
and AC (right) patients from the TMA.

Table 16: Feature analysis. This gives the p-values from the T-test when comparing
patients with AC and SC. From left to right, we compared the mean intensity (M), the
standard deviation (SD) and four x-y symmetric Laws filters (i.e. the outer product of a
given filter with its transpose) and the x-y symmetric half-band filter. The left column
indicates the spectral component image that was filtered.
M

SD

EE

SS

WW

RR

BhBh

x1

0.2637

0.8047

0.4310

0.1163

0.0430

0.0398

0.0514

x2

0.3118

0.7715

0.2779

0.0466

0.0184

0.0243

0.0224

x3

0.3109

0.5260

0.2903

0.0765

0.0382

0.0402

0.0448

The band pass filters from right to left are ordered from high-frequency to low-frequency
band-pass with RR and BhBh both having similar high-frequency band-pass
characteristics. The findings show that the higher frequency filters (WW, RR, and BhBh )
produce a measure that shows a difference across the two histological types with the x2
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(green) component showing greater differences. The M and SD measures showed no
significance from any of the component images or when applying PCA. The differences
in x1-x2, x1-x3, and x3-x2, were also investigated and showed no significance with or
without PCA (not shown). Examples of related textures are shown in Figure 12. Textures
that showed significance were generated synthetically for demonstration by filtering
white-noise with the respective filter kernels. A filter is sensitive to the texture it
generates (i.e. filter texture reciprocity). When comparing the raw images in Figure 11
with the related textures shown in Figure 12, it is not obvious that there are
distinguishable textural differences between the two histology subtypes.

Figure 12: Examples of Laws filters. Laws filters were applied to white-noise fields to
demonstrate three textures: SS (left), WW (middle), and RR (right).

To assess whether the measures bring additional information to the process, the x2
results from WW and RR filtering were used in Cox regression. Using this dataset and
dichotomizing by histology subtype gave HR= 1.77 (0.995, 3.139) showing a baseline
trend in that those with SC are at elevated hazard. Controlling for WW(x2) [i.e. the WW
x2 component] with the two tumor types gave HR=1.95, (1.04, 3.65) indicating the WW
texture measure at this scale complements the tumor categorical variable. Adding RR
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(x2) with WW(x2) as controlling factors did not influence findings. Cox regression was
performed by dichotomizing WW(x2) at its median distribution value (65.8) which gave
HR=1.91 (1.05, 3.47), showing (i) patients with an above median WW(x2) measure have
a significantly elevated hazard, and (ii) the x2 measure at the WW scale is related to
survival.

Because all three of the WW scale measures showed significance, we restricted the
pixel level PCA analysis to this measure and reduced the three images to one image
and applied the WW filter which produced little association (p=0.0391) when comparing
across histology subtypes. Using Cox regression by dichotomizing at the median, which
gave HR = 0.929 (0.522,1.652). We then applied PCA at the summary level and
combined the three standard deviation measures derived from WW which separated the
two tumor types (p=0.035), but was not better than that provided by WW(x2) in isolation
(see Table 17). We then combined W(x2), WW(x3) and RR(x2) with PCA, which also
separated the two groups (p=0.0295), but was not better than provided WW(x2) in
isolation.

In summary, a measure from the TMA green image filtered with the WW or RR Laws
two-dimensional filter kernels was related to both histology subtypes and survival.

5.4.2 Tumor-Grade Associations
The analyses discussed above were repeated on the same dataset to compare the
groups of patients belonging to the three different categories of tumor-grade (i.e.
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grades1-3). Raw tumor image examples for each grade are shown in Figure 13. The
results of SS filtering are shown in Table 17. None of the raw pixel measures (SD, M, or
spectral component differences) showed significance (not shown) or other filters gave
significant results (not shown). In this table for example x1(1,2) indicates a comparison
using grade 1 samples with grade 2 samples from the red image.

Figure 13: Tumor-grade examples. This shows tumor-grade examples for grade 1 (left),
grade 2 (middle), and grade 3 (right) tumors.

Table 17: Texture analysis with the SS filter. This gives the p-values from the T-tests by
comparing patients with the various grades with the red (x1), green (x2) and blue (x3)
components separately. For example, x1(1, 3) is comparing grade 1 and 3 in the red
component.
Red
p-value

x1(1, 2)
0.22

x1(1, 3)
0.03

x1(2, 3)
0.06

Green
p-value

x2(1, 2)
0.16

x2(1, 3)
0.02

x2(2, 3)
0.08

Blue
p-value

x3(1, 2)
0.25

x3(1, 3)
0.02

x3(2, 3)
0.04

As shown in Table 17, most significant differences were found when comparing grade 1
samples with grade 3 samples in all three components (P<0.05). However, the
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difference between grade 2 and 3 was significant only in the blue component giving pvalue= 0.04.

Based on the above results, the measurements of the three SS filtered components (red,
green and blue) were modeled with logistic regression (LR) using a two category grade
system. Grade 1 and grade 2 samples were combined to form one composite grade as
the reference outcome and grade 3 samples formed the other outcome. The measures
of x2 (green) and x3 (blue) components were found to be significantly associated with the
grade: x2 OR = 0.62, (CI: 0.38 0.78) and x3 OR= 0.61, (CI: 0.36 0.88) per SD increase
(SD=23.6 and SD=12.1 respectively). This indicates that a patient with a decreased
texture score is more likely in the grade 1-2 group. These results are consistent with the
findings from the T-test as shown in Table 17. No association was found with survival
outcomes when stratifying by these two modified grade groups (not shown). When
comparing the images shown Figure 14, textural differences are not distinguishable by
observation. As above, PCA was not productive.

The texture analysis using grade as the endpoint found measures related to a hybrid
grading scale. This suggests the stage 1 grade may be better categorized as a twostate problem. It is important to note the most significant grade findings resulted from
the blue and green images using the SS scale. In contrast, the most significant tumortype findings were derived from the WW and RR scales from the green images.
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5.5 Brief Image Analysis Summary
In summary, a method of preparing TMA images for automated processing was
developed and evaluated. Relationships were established relating various image
textures to histology, survival, and tumor-grade indicating the system developed here for
automated TMA analysis is a valid approach.
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Chapter 6: Discussion

Various aspects of stage I NSCLC were investigated using a diverse dataset with a
multifaceted analysis. This evaluation included survival analysis and favorable outcomes
modeling using clinical and pathological variables with accepted epidemiologic
approaches. Novel repair protein expression DNA measures were investigated as
biomarkers for survival. Multivariate models were investigated to determine measures
related to recurrence. A method was developed to integrate kernel based statistical
learning methods with accepted epidemiologic practice, essentially fusing the strengths
of both approaches. A system was developed to analyze tissue microarrays with
automated image processing methods. The various methodologies and findings are
summarized below.

6.1 Baseline Clinical and Pathological Variable Evaluation and Modeling Strategies
For patients with stage I NSCLC, the favorable outcome modeling showed that younger
age and female gender were associated with a favorable survival. These findings were
also observed previously [2, 15, 42]. This analysis demonstrated that the histological
subtype in combination with gender and recurrence provided the greatest predictive
value for a subset of patients. The four category histology-subtypes, tumor-location, and
smoking status were not significant. We also found that increasing age was related to
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the SCC histology subtype, and increasing tumor-grade was related to male gender. The
work also showed that none of the clinical or pathological factors (described in Chapter
2) were related to recurrence.

For the favorable outcomes analysis, a method was established of dichotomizing the
patient population by incident and censored group membership [19], which is a different
approach than taken by other researchers [22]. This approach may be better suited for
limited datasets because it does not require discarding data (see Chapter 2). The
approach can also serve as intermediate step to find variables that may be related to
survival as evaluated with Cox-regression or Kaplan Meier analysis (see Chapter 2 and
Chapter 4).

Notwithstanding the dichotomization approach, it could be argued that the LR favorable
modeling was suboptimal because the time-to-event variable resolution was reduced to
a coarser dichotomous variable. However for a specific set of variables, the LR output
provides a different metric (i.e. probability of having a favorable outcome) than that
provided by Cox regression (i.e. instantaneous relative risk). Moreover, Kaplan-Meier
analysis provided a population level evaluation and is therefore not suited for individual
predictions. Thus, the resolution reduction is the price paid for an alternative output. The
LR modeling (or more generally binary classification) may be more suitable for clinical
based predictions at the patient level because the output is easily interpretable.
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The survival analysis (Kaplan Meier and Cox regression) of the standard clinical and
pathological variables (Chapter 2) clearly showed that younger age, AC histology subtype, negative for disease recurrence, and female gender confer longer survival.
Differences within stage I subgroups were not directly related to survival. However, when
considering patients with certain clinical and pathological factors with stage IA, their
survival prospects were better. Younger age patients with both the AC histology subtype
and Stage IA disease have better survival outcomes. This work showed that tumorgrade was not a significant variable for influencing these patients’ survival outcome
when using accepted approaches, which is in contrast with other findings [2] that also
used accepted approaches. The increased hazard for SCC patients in comparison with
AC, male gender, and increasing age were significantly greater than those found in
related work [2], which may be due to either population or timeframe differences. The
survival findings with adjuvant therapy were consistent with a recent meta-analysis that
documented an increased hazard ratio for adjuvant chemotherapy in patients with stage
IA NSCLC [43], although the findings in this dissertation showed only a trend.

The fact that adjuvant chemotherapy did not influence survival in this cohort of patients
is not surprising. In randomized studies for early stage NSCLC, adjuvant chemotherapy
improved survival for patients with stage II and IIIA disease [44]. For patients with stage
IA disease, a meta-analysis demonstrated a hazard ratio of 1.4 with adjuvant
chemotherapy, suggesting that this group did not benefit. For patients with stage IB
disease, the available evidence indicates that patients with tumor size greater than 4 cm
might benefit from cisplatin-based chemotherapy.
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6.2 Novel Biomarkers
With the advent of molecular and genomic approaches in cancer research, there has
been increased interest in the study of protein biomarkers in clinical tumor tissues [45].
Genomic instability is a significant attribute of cancer cells that facilitates tumor
progression [46]. DNA repair capacity has been shown to be a prognostic factor in
NSCLC patients with resected tumors. Patients with tumors that showed a high ERCC1
expression (i.e. a repair mechanism) had a more favorable prognosis and therefore did
not benefit from adjuvant cisplatin-based chemotherapy [23]. Other proteins involved in
DNA damage repair mechanisms such as Ku86 and PARP have not been studied to any
extent in NSCLC. Thus, it was hypothesized that these repair mechanisms may be
related to survival or recurrence. To the contrary as shown in Chapter 3, PARP and
Ku86 expression did not provide significant associations with favorable outcome,
survival, associations with other variables, or recurrence with the exception that Ku86
expression showed a significant association with male gender. No prognostic
significance was found for these markers in this study population, perhaps because of
the retrospective nature of the study. Nonetheless the observed association between
Ku86 expression and patient gender can inform testable hypotheses to be evaluated
using larger sample sizes and an appropriate matched control group in a prospective
setting. It is notable, agents that modulate PARP and the homologous recombination
repair are currently in clinical studies. Discovering predictive biomarkers for these agents
requires a thorough characterization of expression of the target in the tumor tissue and
other related pathway markers. For this reason, the results of this study are relevant for
drug development efforts with agents that modulate DNA damage repair pathways.
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In summary, the novel biomarker analysis resulted in important negative outcome
experiments. The DNA repair measures were modeled with the clinical and pathological
factors and no significant relationships with survival were found. Moreover, none of
these factors or combination of factors provided significant associations with recurrence.
The prognostic value of recurrence in predicting favorable (or unfavorable) outcome or
survivability may be limited in general because about 64% of the incident and 92% of
censored group patients were negative for recurrence (or unknown for the censored
group). However, positive recurrence is a sure indicator of an unfavorable outcome. A
better understanding of those factors that can predict recurrence is required.

6.3 Statistical Learning and Epidemiology
Cox regression, Kaplan-Meier analysis, and logistic regression (LR) are important and
widely used epidemiologic techniques. These methods are readily available in many
software packages and they provide important epidemiologic interpretations. Cox
regression and LR modeling are parametric and by nature assume a specific output and
input variable covariate forms. The forms can be changed by user imposition. On the
other hand, kernel based statistical learning methods assume no specific data form and
can operate on small datasets with complicated relationships between the covariates
and output. However, SL approaches do not provide a readily interpretable
epidemiologic output and they can require more specialized training techniques that are
often not commercially available.
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A technique for incorporating SL methods with epidemiologic analyses was developed
and evaluated in Chapter 4 [19]. The approach used ensemble averaging with bootstrap
sampling [39] to overcome data limitations. Differential evolution was developed to
determine the kernel weights. This is an evolutionary processing technique for global
optimization problems based on the work by Storn and Price [47]. Age and tumor-grade
were combined with the modified PNN and were used as inputs to logistic regression
and survival analysis (i.e. a hybrid approach). This hybrid approach was compared with
the accepted methods of using these raw clinical variables as inputs. These findings
indicate the hybrid approach provided greater Az in the logistic regression modeling and
greater hazard relationships in the survival analyses than that of the accepted
approaches using the respective variables. In contrast with the findings discussed in
Chapter 2, grade was related to survival outcome when combined with age. The internal
validity of these findings are supported by the cross-validation analysis and the
simulation methods discussed in the Chapter 4. This approach represents a framework
that is easily generalized.

The SL output was used as the input into LR model and survival analysis. This approach
combines the strengths of SL and accepted epidemiologic practice. In this capacity, the
SL device was operating as frontend preprocessing step for these accepted analysis
techniques. Processing the SL output with these approaches provides a mechanism for
converting the SL output into epidemiologic metrics, such as ORs and HRs.

We used a

relatively simple SL device by converting the PPN classifier [29] to give a patient-score
to demonstrate the concept with a two-class probability problem. This specific approach
can be extended to include more than two classes (e.g. death, greater than three, and
five year survival benchmarks). The PNN applies to multiclass problems, as well, and
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multinomial logistic regression can address multiple level outcomes. The PNN classifier
was converted to provide an output score for each patient, which is a different
application. For example, the PNN has been used as a classifier in other types of
survival and medical research [48, 49].

The approach presented in Chapter 4 based on the PNN represents a simplifying step to
demonstrate the main principles. There are more sophisticated methods that can be
used within this SL-epidemiologic framework. More generally, the same hybrid
approach is applicable for the output of any other type of SL method or decision device,
such as support vector machines, kernel based partial least squares, or other types of
neural networks [50-54]. Thus, any combination technique can be used in place of the
modified PNN shown in the schema in Chapter 4.

Generalizations of the LR model, incorporating kernel based techniques, and neural
networks into epidemiologic studies represents a diverse field of inquiry. Neural
networks have been adapted to survival analysis by predicting survival time intervals for
intraocular melanoma [52]. Earlier research used a PNN and LR modeling to predict
survival in early stage NSCLC but did not fuse the models [55]. Logistic regression is a
member of a family of generalized linear models. Replacing the LR argument with
various forms of smooth functions has provided benefits in the study of colon-cancer
[56], heart-disease [57] and infant mortality [58]. Other researchers have incorporated
univariate kernel density estimations for studying prostate-cancer [59], health disparities
[60], and nutrient intake [61]. Similarly, univariate kernel density estimations have been
used to estimate summary measures that were incorporated into LR modeling in fast89

food consumption studies [62]. Our work differs from this other work in that the PNN (or
kernel mapping) application makes no assumption concerning the functional relationship
of the variables under study and we incorporated the measures into LR. Many of the
medical uses of neural networks are reviewed elsewhere [63].

6.4 Image Processing and TMA Data
Tissue microarrays (TMAs) are emerging as an important research tool. These arrays
allow for the analysis of DNA, RNA, and protein expression on a large number of clinical
samples (i.e. tumor samples) simultaneously [64] using laboratory assays such as IHC
or in-situ hybridization [65]. The use of TMAs in comparison with standard whole tumor
sections on slides offers several benefits and major savings in terms scientific resources,
such as use of laboratory reagents, technician effort, pathologist effort etc. Moreover,
recent research with TMAs has led to advancements in quantifying various biomarkers
[66]. The cost for these expanded datasets is that the quality of data in the TMA images
may be degraded compared to conventional pathology slides, as discussed below.
Similarly, different forms of analysis may be required to extract the information from
these expanded dataset. The manufactures of the TMA imaging equipment, as well as
other developers, also provide software for image analyses that is often operator-guided.
For example, work by Behera et al [67] quantified IHC stained TMAs with an operatorguided approach (Aperio, Vista, CA) that resulted in associations between tumor-nuclei
with grade and histology. The novel biomarker analysis presented in Chapter 3 also
used operator-guidance for the measurements. As discussed in this review [64] scoring
methods for TMA images are often subjective, although automated methods are under
development. For example, recent work in lung carcinoma showed that an automated
90

quantitative scoring system for TMAs was significantly correlated with the pathologist
scoring [68].

In this dissertation, a different approach was taken to analyze TMA images. A
customized method was developed to first preprocess the raw images to allow
subsequent automated measurements from the entire dataset simultaneously without
operator imposition or discretion. The preprocessing is essentially a quality control (QC)
procedure that requires operator-input. Various automated image measures were
evaluated. Significant relationships were found with tumor type, survival, and tumorgrade resulting from various Laws filters that capture specific texture characteristics. The
WW (wave) and RR (ripple) filters showed the strongest relationships with the survival
when applied to the green component image. This showed that those with increased
filter-scores were at a significantly elevated hazard. When investigating tumor-grade, the
SS (spot) filter applied to either the blue or green component images showed a
significant relationship between grade 3 patients compared with the combined group of
grade 1 and 2 patients; the blue component image provided the greater associations.
These findings suggest that grade may be better categorized as either a two-state
problem or perhaps as a continuous variable instead of three states for stage 1 patients.
Although grade plays an important role in many tumor types, its prognostic significance
in lung AC has not been established [69]. This is a significant deficiency because the
majority of NSCLC patients have AC. In general, there is higher degree of pathology
concordance for better differentiated tumors and there are no clear standards for
describing moderate and poor differentiation for NSCLC among pathologists [70]. These
texture findings are consistent with the known uncertainty in NSCLC grading. The
various relationships were found at lower resolution and therefore represent preliminary
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findings. We hypothesize that stronger relationships will result when analyzing these
images at higher spatial resolutions.

6.5 Limitations of the Study
There are several limitations associated with our findings, the most significant of which is
the retrospective data collection and limited number of patient samples. This limitation
resulted in incomplete case ascertainment such that the analytic data samples differed
between various evaluations. In the parametric LR modeling, we did not consider
interaction terms in the favorable outcome analysis to limit over-fitting and the
presentation length. We were able to construct logistic regression models with increased
predictive capability by limiting the work to two histology-subtypes, which limits the
model’s applicability. The recurrence variable was unknown for many of the censored
patients, suggesting the related findings are preliminary. The adjuvant treatment
findings should also be qualified because the specific treatment type and regimen were
unknown.

We dichotomized the favorable outcome analysis by censored or incident group
membership, representing a novel separation methodology [19] that will require further
evaluation. This approach reduces the uncertainty in the status for those patients that
did not survive but there are likely patients in the unfavorable group that survived past
some censored group patients. If we assume that the censored group patients did not
expire the day after losing study contact, their censored time is a conservative estimate
(i.e. left-limit) of their overall survival time, indicating that the time separation (mean
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censored and incident times) between the two groups is greater than that specified by
the separation of the censored and incident group means. This indicates that
associations found (ORs or Az) are more likely conservative estimates. Another
approach [22] (that could be considered at the standard approach to dichotomizing
time-to event data) is to use a survival time cut-point to dichotomize the patient
population (i.e. no possibility of overlapping survival time). This approach cannot
accommodate censored patients on the left side of the cut-point (i.e. censored patients
are discarded), which is not practical for limited datasets. This approach may create an
artificial separation when there are many samples near the boundary. In our initial
analyses (not shown), the standard approach using various survival time cut-points was
considered, but was not productive with this dataset. The generality of our approach will
require further evaluation with different datasets.

Although DE is a robust approach, there is no guarantee that it will converge indicating
that the findings may be less than optimal. The generation termination limits were
empirically set. Because, we found that letting the process evolve over many
generations produced weights that were too finely tuned and did not provide
performance consistency between the training evaluation and the final score
assessments. Because the dataset was limited, further evaluation using both simulation
methods and holdout cross-validation with the patient-score was also provided in
chapter 4. The findings from the hybrid modeling will require further evaluations with
different datasets to show generalization. In principle to use the system developed in
Chapter 4 in practice, the sampled patient population should be representative of stage
1 lung cancer patients in general.
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While the TMAs play an important role in cancer research and are widely used for
biomarker studies, they are not routinely used in clinical laboratory testing [65]. One of
the major concerns associated with TMAs are the small size of the tissue cores and that
they may not accurately represent the score obtained from a whole section, due to the
heterogeneous nature of tumor tissue [71, 72]. Hence, multiple cores are usually
extracted per block, taking the tumor heterogeneity into account. Several studies have
validated the use of TMA in various tumor sites [73-75] and have demonstrated
concordance between biomarker scores from TMA and whole sections. The TMA
technology requires sampling of the tumor tissue at regions containing large amounts of
cancer cells. These regions of interest are manually selected by visual assessment of
histology slide images by expert pathologists. Because these methods are new,
standard automated protocols have not yet been developed to identify the regions of
interest in the tumor tissue [66]. Hence, our analyses of the TMA data provided here
were experimental in nature and performed with low spatial resolution data. Related
work in whole slide image analysis has been performed by other researchers [76, 77].

6.6 Conclusions
The work produced several important findings. Baseline survival characteristic were
estimated for a southeastern contemporary population. This is important because lung
cancer survival patterns differ regionally and serially. In addition, these measures can
serve as a baseline to assess whether new measures bring additional information to the
analysis as in Chapter 3. The DNA repair expression variables were not related to
survival, although some associations with SCC and gender in models that included Ku86
score were found [14]. The worked showed the significance of recurrence limiting
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survival, which was known [78, 79]. However, none of the clinical or pathological
variables, novel biomarkers, or combinations of these measures were related to
recurrence, indicating more work is required to find measured related to recurrence. A
platform was established and evaluated to integrate SL techniques with accepted
epidemiologic practice. In conjunction, a technique was developed as an efficiency step
to assist in finding variables that may be related to survival via Cox regression or Kaplan
Meier analysis. A system was developed to analyze TMA images with automated
measures that first requires operator-input as a QC procedure. Once developing the QC
system, it takes about 30 minutes to prepare one microarray image for automated
processing. This system was evaluated with TMA images resulting from standard stains.
Measures related to survival, tumor-type, and tumor grade were established with this
system.

Standard statistical methods and experimental methods were developed to analyze the
clinical and pathological characteristics of this cohort. Several relationships related to
survival and tumor characteristics were quantified. These findings may have
importance to determine optimal therapy and level of aggression required to manage
stage I NSCLC, specifically. Future work includes (i) investigating novel stains and
biomarkers with the system developed in Chapter 5 using higher resolution images and
extending the SL methods developed and evaluated in Chapter 4 to build more general
models, (ii) applying the methods developed here to our parallel work in lung cancer
maintenance therapy [7] and the analysis of SCLC [10] as well, and (iii) the continued
development and expansion of the web-based database in support of our scientific aims
[20]. The longer-term goal is to develop models for use at the individual prediction level
for patients with all forms of lung cancer and for understanding lung cancer etiology.
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